FILE 'HOME' ENTERED AT 10:57:26 ON 18 AUG 2003

=> file medicine and bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
'AND' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 10:57:55 ON 18 AUG 2003

FILE 'CAPLUS' ENTERED AT 10:57:55 ON 18 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'DRUGB' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IPA' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 10:57:55 ON 18 AUG 2003

FILE 'NAPRALERT' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 10:57:55 ON 18 AUG 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 10:57:55 ON 18 AUG 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHARMAML' ENTERED AT 10:57:55 ON 18 AUG 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 10:57:55 ON 18 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:57:55 ON 18 AUG 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 10:57:55 ON 18 AUG 2003

FILE 'ANABSTR' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CABA' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CEABA-VTB' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CIN' ENTERED AT 10:57:55 ON 18 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGUPDATES' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'FEDRIP' ENTERED AT 10:57:55 ON 18 AUG 2003

FILE 'FOMAD' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 10:57:55 ON 18 AUG 2003

FILE 'HEALSAFE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'NIOSHTIC' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 10:57:55 ON 18 AUG 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'OCEAN' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PHAR' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SYNTHLINE' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'VETB' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 10:57:55 ON 18 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s glucagon (w) like (w) peptide-1 and (ischemic? or reperfused (w) tissue#)
L1 0 FILE ADISCTI
L2 0 FILE ADISINSIGHT
L3 0 FILE ADISNEWS
L4 1 FILE BIOSIS
L5 1 FILE BIOTECHNO
L6 0 FILE CANCERLIT
L7 6 FILE CAPLUS
L8 0 FILE CEN
L9 13 FILE DGENE
L10 0 FILE DRUGB
L11 0 FILE DRUGLAUNCH
L12 0 FILE DRUGMONOG2
L13 0 FILE DRUGNL
L14 2 FILE DRUGU
L15 1 FILE EMBAL
L16 5 FILE EMBASE
L17 1 FILE ESBIOBASE
L18 5 FILE IFIPAT
L19 0 FILE IPA
L20 0 FILE JICST-EPLUS
L21 0 FILE KOSMET
L22 0 FILE LIFESCI
L23 0 FILE MEDICONF
L24 1 FILE MEDLINE
L25 0 FILE NAPRALERT
L26 2 FILE NLDB
L27 0 FILE NUTRACEUT
L28 0 FILE PASCAL
L29 0 FILE PCTGEN

```
L30           0 FILE PHARMAML
L31           0 FILE PHIC
L32           0 FILE PHIN
L33           2 FILE SCISEARCH
L34           1 FILE TOXCENTER
L35          33 FILE USPATFULL
L36           2 FILE USPAT2
L37           0 FILE AGRICOLA
L38           0 FILE ANABSTR
L39           0 FILE AQUASCI
L40           0 FILE BIOBUSINESS
L41           0 FILE BIOCOMMERCE
L42           0 FILE BIOTECHDS
L43           0 FILE CABA
L44           0 FILE CEABA-VTB
L45           0 FILE CIN
L46           0 FILE CONFSCI
L47           0 FILE CROPB
L48           0 FILE CROPU
L49           0 FILE DRUGUPDATES
L50           0 FILE FEDRIP
L51           0 FILE FOMAD
L52           0 FILE FOREGE
L53           0 FILE FROSTI
L54           0 FILE FSTA
L55           0 FILE GENBANK
L56           0 FILE HEALSAFE
L57           0 FILE NIOSHTIC
L58           0 FILE NTIS
L59           0 FILE OCEAN
L60           0 FILE PHAR
L61           2 FILE PROMT
L62           0 FILE RDISCLOSURE
L63           0 FILE SYNTHLINE
L64           0 FILE VETB
L65           0 FILE VETU
L66           6 FILE WPIDS

TOTAL FOR ALL FILES
L67          84 GLUCAGON (W) LIKE (W) PEPTIDE-1 AND (ISCHEMIC? OR REPERFUSED
                (W) TISSUE#)

=> dup rem l67
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH,
DRUGMONOG2, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML, BIOCOMMERCE,
DRUGUPDATES, FEDRIP, FOREGE, GENBANK, PHAR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L67
L68           62 DUP REM L67 (22 DUPLICATES REMOVED)

=> d l68 1-62 ibib abs

L68  ANSWER 1 OF 62  CAPLUS  COPYRIGHT 2003 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2003:300601  CAPLUS
DOCUMENT NUMBER:          138:298126
TITLE:                    Compositions and methods for treating peripheral
                          vascular disease with GLP-1 compounds
INVENTOR(S):              Hathaway, David R.; Coolidge, Thomas R.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S.
                          Ser. No. 851,738.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073626	A1	20030417	US 2002-91258	20020305
US 6284725	B1	20010904	US 1999-302596	19990430
US 2002055460	A1	20020509	US 2001-851738	20010509

PRIORITY APPLN. INFO.: US 1999-302596 A3 19990430
US 2001-851738 A2 20010509
US 1998-103498P P 19981008

AB The present invention relates to methods of treating intermittent claudication comprising administering **glucagon-like peptide-1** (GLP-1) mols. to subjects suffering therefrom. A method of treating or preventing skeletal muscle injury caused by ischemia and/or reperfusion in a subject comprising the step of administering a therapeutically effective amt. of GLP-1 mol. is also claimed. The subject can also be administered free radical scavengers, glucose, or potassium. The GLP-1 compd. is administered by an infusion pump or by s.c. injection of a slow-release formulation.

L68 ANSWER 2 OF 62 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:551365 CAPLUS
DOCUMENT NUMBER: 139:111703
TITLE: Method and composition using a dipeptidyl peptidase IV inhibitor-neutral endopeptidase inhibitor combination for treatment of diabetes, hypertension, chronic heart failure, and fluid retentive states
INVENTOR(S): Carr, Richard David
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057200	A2	20030717	WO 2003-DK17	20030113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DK 2002-47 A 20020111
US 2002-348332P P 20020114

AB The invention provides a method and compn. for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states, comprising administering inhibitors of neutral endopeptidase and dipeptidyl peptidase IV (DPP-IV) to individuals suffering from one or more of these conditions. Inhibition of the activity of the two enzymes will potentiate the insulin-releasing activity of endogenous **glucagon-like peptide 1** (GLP-1) and other DPP-IV substrates, e.g. gastric inhibitory peptide (GIP). Prepn. of heterocyclic DPP-IV inhibitors is described.

L68 ANSWER 3 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:214384 USPATFULL
TITLE: 1,5-benzodiazepine compounds, their production and use

INVENTOR(S): Oi, Satoru, Nara-shi, JAPAN
Suzuki, Nobuhiro, Tsukuba-shi, JAPAN
Matsumoto, Takahiro, Kawabe-gun, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003149027	A1	20030807
APPLICATION INFO.:	US 2001-894105	A1	20010628 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-298941	19981020

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 5350

AB A compound represented by the formula (I) ##STR1##

[wherein ring B represents a cyclic hydrocarbon group which may have substituent(s); Z represents hydrogen atom or a cyclic group which may have substituent(s); R.sup.1 represents hydrogen atom, a hydrocarbon group which may have substituent(s), a heterocyclic group which may have substituent(s) or an acyl group; R.sup.2 represents amino group which may have substituent(s); D represents a bond or a divalent group; E represents a bond, --CO--, --CON(R.sup.a)--, --COO--, --N(R.sup.a)CON(R.sup.b)--, --N(R.sup.a)COO--, --N(R.sup.a)SO.sub.2--, --N(R.sup.a)--, --O--, --S--, --SO-- or --SO.sub.2-- (R.sup.a and R.sup.b each independently represents hydrogen atom or a hydrocarbon group which may have substituent(s)); G represents a bond or a divalent group; L represents a bond or a divalent group; A represents hydrogen atom or a substituent; X and Y each represents hydrogen atom or an independent substituent; and . . . represents that R.sup.2 and an atom on ring B may form a ring] or a salt thereof, and a process for producing the same.

L68 ANSWER 4 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:207926 USPATFULL
TITLE: Novel N-[4- (1H-imidazol-1-yl) -2-fluorophenyl] -3- (trifluoromethyl) -1H-pyrazole-5-carboxamides as factor Xa inhibitors
INVENTOR(S): Quan, Mimi L., Newark, DE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144287	A1	20030731
APPLICATION INFO.:	US 2002-302184	A1	20021122 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336972P	20011204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1577

AB The present application describes N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides and derivatives thereof of, which are useful as inhibitors of factor Xa.

L68 ANSWER 5 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:200433 USPATFULL
TITLE: Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
INVENTOR(S): Lau, Jesper, Farum, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003138416	A1	20030724	
APPLICATION INFO.:	US 2002-308355	A1	20021203	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DK 2001-1789	20011203	
	DK 2001-1917	20011219	
	DK 2001-1925	20011220	
	DK 2002-1006	20020627	
	DK 2002-999	20020627	
	DK 2002-1117	20020718	
	EP 2002-388015	20020219	
	US 2001-336876P	20011205	(60)
	US 2001-342428P	20011220	(60)
	US 2001-342355P	20011220	(60)
	US 2001-386185P	20011221	(60)
	US 2002-394145P	20020703	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 1169
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of a combination of a glucokinase activator and a glucagon antagonist for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity and inhibiting the activity of glucagon is beneficial, such as for management, treatment, control, or adjunct treatment of type 1 diabetes or type 2 diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 6 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:140985 USPATFULL
TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
INVENTOR(S): Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES
Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096827	A1	20030522	
APPLICATION INFO.:	US 2002-90288	A1	20020304	(10)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2001-273206P	20010302 (60)
	US 2001-273291P	20010302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2509	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula (I), ##STR1##

NR.sub.11R.sub.12; G is a novel side chain selected from C.sub.2-6alkenyl, A.sub.3-aryl, --OR.sub.18, heteroaryl, A.sub.1-cyano, A.sub.2--OR.sub.17, A.sub.1--C(.dbd.O)R.sub.18, A.sub.1--CO.sub.2R.sub.18, A.sub.1--C(.dbd.O)NR.sub.18R.sub.19, A.sub.1--OC(.dbd.O)R.sub.18, A.sub.1--NR.sub.18C(.dbd.O)R.sub.19, A.sub.1--OC(.dbd.O)NR.sub.18R.sub.19, A.sub.1--NR.sub.18CO.sub.2R.sub.19, A.sub.1--NR.sub.18SO.sub.2R.sub.17, A.sub.1--SO.sub.2R.sub.17, A.sub.1--NR.sub.20C(.dbd.O)NR.sub.18R.sub.19, and A.sub.1--SR.sub.18; or when y is 0 or when W is not NHR.sub.22, G may be A.sub.1-heterocyclo, wherein A.sub.1 is a bond, C.sub.1-6alkylene or C.sub.2-alkenylene, A.sub.2 is C.sub.1-6alkylene or C.sub.2-6alkenylene, and A.sub.3 is C.sub.2-6alkenylene; W is selected from --NR.sub.21R.sub.22, --OR.sub.23, --NR.sub.21C(.dbd.O)R.sub.24, --NR.sub.21CO.sub.2R.sub.24, amidino, guanidino, or a heteroaryl, heterocyclo or C.sub.3-7cycloalkyl as defined in the specification, and X and R.sub.1 through R.sub.24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 7 OF 62 USPATFULL on STN

ACCESSION NUMBER:	2003:134643 USPATFULL	
TITLE:	Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same	
INVENTOR(S):	Yu, Guixue, Lawrenceville, NJ, UNITED STATES Macor, John, Guilford, CT, UNITED STATES Herpin, Timothy, Princeton, NJ, UNITED STATES Lawrence, R. Michael, Yardley, PA, UNITED STATES Morton, George C., Collegeville, PA, UNITED STATES Ruel, Rejean, Saint-Lambert, CANADA Poindexter, Graham S., Old Saybrook, CT, UNITED STATES Ruediger, Edward H., Greenfield Park, CANADA Thibault, Carl, Mascouche, CANADA	

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092732	A1	20030515	
APPLICATION INFO.:	US 2002-90582	A1	20020304	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-273206P	20010302 (60)
	US 2001-273291P	20010302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2878	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, ##STR1##

in which E is

X is N or CH, W is --NR.sub.16R.sub.17, --NR.sub.16C(.dbd.O)R.sub.22, --NR.sub.16CO.sub.2R.sub.22, --OR.sub.23, or a heteroaryl or heterocyclo group as defined in the specification, and R.sub.1 through R.sub.12, R.sub.16, R.sub.17, R.sub.22, R.sub.23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 8 OF 62 USPATFULL on STN

ACCESSION NUMBER: 2003:112529 USPATFULL

TITLE: Induction of beta cell differentiation in human cells

INVENTOR(S): Levine, Fred, Del Mar, CA, UNITED STATES
Gouty, Dominique, San Diego, CA, UNITED STATES
Itkin-Ansari, Pamela, Carlsbad, CA, UNITED STATES

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003077259	A1	20030424	
APPLICATION INFO.:	US 2001-41845	A1	20011018	(10)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 1448

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for inducing insulin gene expression in cultured pancreas cells, the method comprising contacting a culture of endocrine pancreas cells expressing a PDX-1 gene and a NeuroD/BETA2 gene with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions such that the cells are in contact with other cells in the culture, thereby inducing insulin gene expression in the cells. The invention also provides high throughput screening methods for modulators of .beta.-cell function, stable cultures of cells made by the methods of the invention, and methods of treating a human subject using the methods of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 9 OF 62 USPATFULL on STN

ACCESSION NUMBER: 2003:100059 USPATFULL

TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

INVENTOR(S): Macor, John E., Guilford, CT, UNITED STATES
Carlson, Kenneth E., West Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003069169	A1	20030410	
APPLICATION INFO.:	US 2002-90258	A1	20020304	(10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2001-273206P 20010302 (60)
US 2001-273291P 20010302 (60)
US 2001-289719P 20010509 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 10 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:65326 USPATFULL
TITLE: Methods of providing symptomatic and prophylactic neuroprotection
INVENTOR(S): Kozachuk, Walter E., Kensington, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045450	A1	20030306
APPLICATION INFO.:	US 2002-212765	A1	20020807 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-799051, filed on 6 Mar 2001, PENDING Continuation-in-part of Ser. No. US 1996-632338, filed on 10 Apr 1996, GRANTED, Pat. No. US 5728728
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LINIAK BERENATO LONGACRE & WHITE, SUITE 240, 6550 ROCK SPRING DRIVE, BETHESDA, MD, 20817
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are disclosed for prophylactically and chronically preventing symptomatic depression, neuronal cell injury and cell death in systemic and neurological conditions, populations with cerebrovascular risk factors, and invasive vascular procedures, employing a glycine-site antagonist at the NMDA (N-methyl-D-aspartate) complex e.g., 2-phenyl-1,3-propanediol dicarbamate (felbamate).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 11 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:57903 USPATFULL
TITLE: Lowering serum lipids
INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003040469	A1	20030227

APPLICATION INFO.: US 2001-800541 A1 20010307 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-375	20000308
	US 2000-191593P	20000320 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6400
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 2265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for lowering serum lipids in a patient by administering a GLP-1 agonist. The invention is useful for treating diseases that may be alleviated by lowering serum lipid levels, including, e.g., cardiovascular disease and diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 12 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:176402 USPATFULL
TITLE: Methods of enhancing functioning of the large intestine
INVENTOR(S): Drucker, Daniel J., Ontario, CANADA
PATENT ASSIGNEE(S): 1149336 Ontario, Inc., Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6586399	B1	20030701
APPLICATION INFO.:	US 2000-692238		20001020 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-149831, filed on 8 Sep 1998, now patented, Pat. No. US 6297214
Continuation-in-part of Ser. No. US 1997-850664, filed on 2 May 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Kam, Chih-Min
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 13 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:137062 USPATFULL
TITLE: Positively charged non-natural amino acids, methods of making and using thereof in peptides
INVENTOR(S): Dix, Thomas A., Mt. Pleasant, SC, United States
PATENT ASSIGNEE(S): Medical University of South Carolina Foundation Research Development, Charleston, SC, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6566330	B1	20030520
APPLICATION INFO.:	US 2000-659665		20000911 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-452575, filed on 1 Dec 1999 Division of Ser. No. US 1996-736049, filed on 22 Oct 1996, now patented, Pat. No. US 6043218
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Needle & Rosenberg, P.C.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2184
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 14 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2003:136926 USPATFULL
TITLE: Assay for and uses of peptide hormone receptor agonists
INVENTOR(S): Kopin, Alan S., Wellesley, MA, United States
Beinborn, Martin, Brookline, MA, United States
PATENT ASSIGNEE(S): New England Medical Center, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6566080	B1	20030520
APPLICATION INFO.:	US 1998-4349		19980108 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-718047, filed on 3 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1995-570157, filed on 11 Dec 1995, now patented, Pat. No. US 5750353
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Clark & Elbing LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for determining whether a candidate compound is a non-peptide agonist of a peptide hormone receptor. In this method, a candidate compound is exposed to a form of the peptide hormone receptor, or to a protein that interacts with a peptide hormone receptor, which has an enhanced ability to amplify the intrinsic activity of a non-peptide agonist. The second messenger signaling activity of the enhanced receptor is measured in the presence of the candidate compound, and compared to the second messenger signaling activity of the wildtype receptor measured in the absence of the candidate compound. A change in second messenger signaling activity indicates that the candidate compound is an agonist. An increase in second messenger signaling activity indicates that the compound is either a full or partial positive agonist; a decrease in second messenger signaling activity indicates that the compound is an inverse (also termed a `negative`) agonist. The invention further embraces a method of using a peptide hormone receptor agonist for the treatment or prevention of a physiological disease, as well as particular enhanced

receptors and the nucleic acid sequences which code for them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 15 OF 62 USPATFULL on STN

ACCESSION NUMBER:	2003:123105 USPATFULL
TITLE:	Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
INVENTOR(S):	Lin, Henry C., Manhattan Beach, CA, United States
PATENT ASSIGNEE(S):	Cedars-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6558708	B1	20030506
APPLICATION INFO.:	US 2000-546119		20000410 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-420046, filed on 18 Oct 1999 Continuation-in-part of Ser. No. US 1999-359583, filed on 22 Jul 1999, now abandoned Continuation of Ser. No. US 1997-832307, filed on 3 Apr 1997, now patented, Pat. No. US 5977175, issued on 2 Nov 1999 Continuation of Ser. No. US 1995-442843, filed on 17 May 1995, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Tran, S.
LEGAL REPRESENTATIVE:	Sidley Austin Brown & Wood LLP
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:	3377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 16 OF 62 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN

ACCESSION NUMBER:	2003227197 EMBASE
TITLE:	Clinical significance, pathogenesis, and management of postprandial hyperglycemia.
AUTHOR:	Gerich J.E.
CORPORATE SOURCE:	Dr. J.E. Gerich, Univ. of Rochester Medical Center, Box MED/CRC, 601 Elmwood Ave, Rochester, NY 14642, United States. mary_little@urmc.rochester.edu
SOURCE:	Archives of Internal Medicine, (9 Jun 2003) 163/11 (1306-1316). Refs: 128 ISSN: 0003-9926 CODEN: AIMDAP
COUNTRY:	United States
DOCUMENT TYPE:	Journal; General Review

FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
AB It is well established that strict glycemic control (hemoglobin A(1c) <7.0%) can prevent the microvascular complications of diabetes mellitus. Recent studies indicate that elevated plasma glucose concentrations are an independent and clinically significant risk factor for cardiovascular disease in nondiabetic and diabetic individuals. Thus, isolated postprandial hyperglycemia (2-hour postprandial glucose level >140 mg/dL [>7.8 mmol/L]) in the face of normal fasting plasma glucose (<110 mg/dL [<6.1 mmol/L]) and normal hemoglobin A(1c) (<6.1%) values is associated with a 2-fold increased risk of death from cardiovascular disease. These observations imply that more strict glycemic control is required to prevent macrovascular disease than microvascular disease. This review summarizes epidemiologic and experimental studies linking postprandial hyperglycemia to cardiovascular disease and therapeutic approaches available and in development to treat this disorder.

L68 ANSWER 17 OF 62 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2003:519511 CAPLUS
TITLE: **Glucagon-like peptide-1** (7-36) amide prevents the accumulation of pyruvate and lactate in the **ischemic** and non-**ischemic** porcine myocardium
AUTHOR(S): Kavianipour, Mohammad; Ehlers, Mario R.; Malmberg, Klas; Ronquist, Gunnar; Ryden, Lars; Wikstrom, Gerhard; Gutniak, Mark
CORPORATE SOURCE: Department of Public Health and Clinical Medicine, Umea University Hospital, Umea, Swed.
SOURCE: Peptides (New York, NY, United States) (2003), 24(4), 569-578
CODEN: PPTDD5; ISSN: 0196-9781
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB **Glucagon-like peptide-1** (7-36) amide (GLP-1) has been studied as a treatment option in diabetic patients. We investigated the effect of recombinant GLP-1 infusion on hemodynamic parameters, myocardial metab., and infarct size during normoxic conditions as well as during ischemia and reperfusion using an open-chest porcine heart model. In the presence of rGLP-1, interstitial levels of pyruvate and lactate decreased during ischemia and reperfusion both in **ischemic** and non-**ischemic** tissue. Moreover, rGLP-1 infusion resulted in increased plasma insulin levels and decreased blood glucose levels. Neither hemodynamic variables nor the consequent infarct size were influenced by rGLP-1 infusion. We conclude that rGLP-1 altered myocardial glucose utilization during ischemia and reperfusion. It did not exert any untoward hemodynamic effects.

L68 ANSWER 18 OF 62 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 2003120756 EMBASE
TITLE: Insulin sensitation in the treatment of type 2 diabetes.
AUTHOR: Tadayyon M.; Smith S.A.
CORPORATE SOURCE: Dr. S. Smith, Scientific Strategy - Metabolism, Global Commercial Strategy, GlaxoSmithKline, Third Avenue, Harlow CM19 5AW, Germany. Stephen_A_Smith@gsk.com
SOURCE: Expert Opinion on Investigational Drugs, (1 Mar 2003) 12/3 (307-325).
Refs: 113
ISSN: 1354-3784 CODEN: EOIDER
COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
017 Public Health, Social Medicine and Epidemiology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Type 2 diabetes is reaching epidemic proportions worldwide, fuelled by the increasing prevalence of obesity as many populations adopt a western lifestyle. Secondary complications affecting both the microvascular and macrovascular systems are responsible for premature mortality in Type 2 diabetes, with two thirds or more dying of cardiovascular disease. Two interacting metabolic defects, insulin resistance and .beta.-cell dysfunction are present in Type 2 diabetes. It is now recognised that insulin resistance is central to a cluster of metabolic abnormalities - called the insulin resistance syndrome - that are responsible for the excess of cardiovascular disease. Older antidiabetic agents such as the sulfonylureas, metformin and insulin are more effective than lifestyle modification in reducing microvascular complications of Type 2 diabetes, but overall do not reduce cardiovascular risk. Metformin, although no more effective as a glucose-lowering agent than sulfonylureas or insulin, does significantly reduce cardiovascular disease, probably as a result of its weak insulin-sensitising action. The newly-marketed thiazolidinedione insulin-sensitising antidiabetic agents also improve multiple biomarkers of cardiovascular risk, suggesting that novel approaches to insulin sensitisation will not only provide effective long-term glycaemic control but improve cardiovascular outcomes in Type 2 diabetes. Multiple therapeutic targets within the insulin signalling cascade are being explored, together with follow-up compounds to the first generation thiazolidinediones. These initiatives, together with developments in .beta.(3)-adrenoceptor agonists, 11.beta.-hydroxysteroid dehydrogenase Type 1 inhibitors and modulators of the **glucagon-like peptide 1** axis, all of which also potentially enhance insulin sensitivity, are critically evaluated.

L68 ANSWER 19 OF 62 IFIPAT COPYRIGHT 2003 IFI on STN DUPLICATE 3
AN 10203424 IFIPAT;IFIUDB;IFICDB
TITLE: METABOLIC INTERVENTION WITH GLP-1 TO IMPROVE THE FUNCTION OF **ISCHEMIC** AND REPERFUSED SKELETAL MUSCLE TISSUE
INVENTOR(S): Coolidge; Thomas R., Falls Village, CT, US
Ehlers; Mario R.W., Lincoln, NE, US
PATENT ASSIGNEE(S): Unassigned
AGENT: MCKEE, VOORHEES & SEASE, P.L.C. ATTN: BIONEBRASKA, 801 GRAND AVENUE, SUITE 3200, DES MOINES, IA, 50309-2721, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002147131	A1	20021010
APPLICATION INFORMATION:	US 2001-953021		20010911

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 2001-851738	20010509	PENDING
DIVISION OF:	US 1999-302596	19990430	6284725

	NUMBER	DATE	
PRIORITY APPLN. INFO.:	US 1998-103498P	19981008	(Provisional)
FAMILY INFORMATION:	US 2002147131	20021010	
	US 6284725		

DOCUMENT TYPE: Utility

Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 23
AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagonlike peptide-1. The invention relates to both the method and compositions for such treatment.
CLMN 23

L68 ANSWER 20 OF 62 IFIPAT COPYRIGHT 2003 IFI on STN DUPLICATE 4
AN 10111853 IFIPAT;IFIUDB;IFICDB
TITLE: METABOLIC INTERVENTION WITH GLP-1 TO IMPROVE THE FUNCTION OF **ISCHEMIC** AND **REPERFUSED** **TISSUE**; ADMINSTERING A COMPOUND THAT BINDS TO A RECEPTOR FOR THE **GLUCAGON-LIKE** **PEPTIDE-1** (GLP-1)
INVENTOR(S): Coolidge; Thomas R., Falls Village, CT, US
Ehlers; Mario R.W., Lincoln, NE, US
PATENT ASSIGNEE(S): Unassigned
AGENT: MCKEE, VOORHEES & SEASE, P.L.C. ATTN: BIONEBRASKA, 801 GRAND AVENUE, SUITE 3200, DES MOINES, IA, 50309-2721, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002055460	A1	20020509
APPLICATION INFORMATION:	US 2001-851738		20010509

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
DIVISION OF:	US 1999-302596	19990430	6284725

	NUMBER	DATE	
PRIORITY APPLN. INFO.:	US 1998-103498P	19981008	(Provisional)
FAMILY INFORMATION:	US 2002055460	20020509	
	US 6284725		

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 23
AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagonlike peptide-1. The invention relates to both the method and compositions for such treatment.
CLMN 23

L68 ANSWER 21 OF 62 IFIPAT COPYRIGHT 2003 IFI on STN DUPLICATE 5
AN 3728478 IFIPAT;IFIUDB;IFICDB
TITLE: METABOLIC INTERVENTION WITH GLP-1 OR ITS BIOLOGICALLY ACTIVE ANALOGUES TO IMPROVE THE FUNCTION OF THE **ISCHEMIC** AND REPERFUSED BRAIN; INTRAVENOUS ADMINISTRATION OF **GLUCAGON-LIKE** **PEPTIDE 1** (GLP-1) TO OPTIMIZE INSULIN SECRETION; MINIMIZES RISK OF HYPOGLYCEMIA
INVENTOR(S): Coolidge; Thomas R., Falls Village, CT
Ehlers; Mario R. W., Lincoln, NE
PATENT ASSIGNEE(S): Bionebraska, Inc., Lincoln, NE
PRIMARY EXAMINER: Low, Christopher S. F
ASSISTANT EXAMINER: Mohamed, Abdel A
AGENT: McKee, Voorhees & Sease, P.L.C.

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6429197		20020806
APPLICATION INFORMATION:	US 1999-303016		19990430
EXPIRATION DATE:	30 Apr 2019		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 1998-103498P	19981008 (Provisional)
FAMILY INFORMATION:	US 6429197	20020806
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
NUMBER OF CLAIMS:	10	

AB It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.

CLMN 10

L68 ANSWER 22 OF 62 USPATFULL on STN DUPLICATE 6

ACCESSION NUMBER: 2002:259599 USPATFULL

TITLE: Compounds derived from an amine nucleus and pharmaceutical compositions comprising same

INVENTOR(S): Liu, Chunjian, Pennington, NJ, UNITED STATES
Dhar, T.G. Murali, Newtown, PA, UNITED STATES
Gu, Henry H., Bordentown, NJ, UNITED STATES
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
Leftheris, Katerina, Skillman, NJ, UNITED STATES
Pitts, William J., Newtown, PA, UNITED STATES
Herpin, Timothy F., Princeton, NJ, UNITED STATES
Pi, Zulan, Pennington, NJ, UNITED STATES
Bisacchi, Gregory S., Ringoes, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002143176	A1	20021003
	US 6596747	B2	20030722
APPLICATION INFO.:	US 2001-997963	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-428432, filed on 27 Oct 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106186P	19981029 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2608	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula (I), ##STR1##

are effective as inhibitors of IMPDH enzyme and/or serine protease Factor VIIa, wherein B is a monocyclic or bicyclic carbocyclic or heterocyclic ring, D is a monocyclic or bicyclic carbocyclic or heterocyclic ring except when A is a heterocyclic ring, then D is a heterocyclic ring system, R is hydrogen or C.sub.1-4alkyl, and A, R.sub.1, R.sub.2 and R.sub.4 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 23 OF 62 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10163558 IFIPAT;IFIUDB;IFICDB
TITLE: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1; ADMINISTERING **GLUCAGON LIKE PEPTIDE-1** (GLP-1), WHERE THE PATIENT IS NOT SUFFERING FROM A Q-WAVE MYOCARDIAL INFARCTION
INVENTOR(S): Coolidge; Thomas R., Falls Village, CT, US
Ehlers; Mario, Lincoln, NE, US
PATENT ASSIGNEE(S): Unassigned
AGENT: Beth A. Burrous FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W. Suite 500 Washington, DC, 20007-5109, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002107206	A1	20020808
APPLICATION INFORMATION:	US 2001-859804		20010518

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2000-205239P	20000519 (Provisional)
FAMILY INFORMATION:	US 2002107206	20020808

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 47
AB The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.
CLMN 47

L68 ANSWER 24 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2002:265533 USPATFULL
TITLE: Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
INVENTOR(S): Coolidge, Thomas R., Falls Village, CT, UNITED STATES
Ehlers, Mario, Lincoln, NE, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002146405	A1	20021010	
APPLICATION INFO.:	US 2001-982978	A1	20011022	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-241834P	20001020 (60)
	US 2000-242139P	20001023 (60)
	US 2000-245234P	20001103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Hibernating myocardium is characterized by viable myocardium with

impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 25 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2002:251777 USPATFULL
TITLE: Positively charged non-natural amino acids, methods of making and using thereof in peptides
INVENTOR(S): Dix, Thomas A., Mt. Pleasant, SC, UNITED STATES
PATENT ASSIGNEE(S): Medical University of South Carolina (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137730	A1	20020926
APPLICATION INFO.:	US 2002-92287	A1	20020306 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-659665, filed on 11 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-452575, filed on 1 Dec 1999, GRANTED, Pat. No. US 6358922 Division of Ser. No. US 1996-736049, filed on 22 Oct 1996, GRANTED, Pat. No. US 6043218
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NEEDLE & ROSENBERG P C, 127 PEACHTREE STREET N E, ATLANTA, GA, 30303-1811
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 26 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2002:165232 USPATFULL
TITLE: Fused 1,2,4- thiadiazine derivatives, their preparation and use
INVENTOR(S): Hansen, John Bondo, Jyderup, DENMARK
Nielsen, Flemming Elmelund, Virum, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086861	A1	20020704
APPLICATION INFO.:	US 2001-12145	A1	20011207 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-464979, filed on 16 Dec 1999, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1998-1693	19981218
	DK 1999-18	19990111
	US 1999-115544P	19990112 (60)
	US 1999-116438P	19990120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Nova Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY,

10174-6401
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 1153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 4H-thieno[3,2-e]-1,2,4-thiadiazine derivatives of the general formula: ##STR1##

wherein X, Y, R.sup.1, R.sup.2 and R.sup.3 are defined in the description, compositions thereof and methods for preparing the compounds are described.

The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 27 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2002:133843 USPATFULL
TITLE: Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
INVENTOR(S): Dix, Thomas A., Mt. Pleasant, SC, UNITED STATES
PATENT ASSIGNEE(S): Medical University of South Carolina (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068701	A1	20020606
APPLICATION INFO.:	US 2002-43581	A1	20020110 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-452575, filed on 1 Dec 1999, PATENTED Division of Ser. No. US 1996-736049, filed on 22 Oct 1996, PATENTED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gwendolyn D. Spratt, Esq., NEEDLE & ROSENBERG, P.C., The Candler Building, Suite 1200, 127 Peachtree Street, N.E., Atlanta, GA, 30303-1811
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 28 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2002:57759 USPATFULL
TITLE: Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
INVENTOR(S): Dix, Thomas A., Mt. Pleasant, SC, United States
PATENT ASSIGNEE(S): Medical University of South Carolina, Charleston, SC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358922	B1	20020319
APPLICATION INFO.:	US 1999-452575		19991201 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-736049, filed on 22 Oct 1996, now patented, Pat. No. US 6043218
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huff, Sheela

LEGAL REPRESENTATIVE: Needle & Rosenberg, P.C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 29 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2002:45607 USPATFULL
TITLE: 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
INVENTOR(S): Mabuchi, Hiroshi, Nara, JAPAN
Suzuki, Nobuhiro, Tsukuba, JAPAN
Miki, Takashi, Osaka, JAPAN
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6352982	B1	20020305	
	WO 9847882		19981029	
APPLICATION INFO.:	US 1999-403066		19991014	(9)
	WO 1998-JP1797		19980420	
			19991014	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-103138	19970421
	JP 1997-319545	19971120

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
ASSISTANT EXAMINER: Liu, Hong
LEGAL REPRESENTATIVE: Riesen, Philippe Y., Chao, Mark
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 10436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a compound of the formula: ##STR1##

wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R.sup.1 is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R.sup.2 is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, --CON(R.sup.a)--, --N(R.sup.a)CO--, --N(R.sup.b)CON(R.sup.c)--, --N(R.sup.d)COO--, --N(R.sup.e)SO.sub.2--, --COO--, --N(R.sup.f)--, --O--, --S-- --SO--, --SO.sub.2--, ##STR2##

(in which R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e and R.sup.f are respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group;

ring B may form an optionally substituted non-aromatic condensed nitrogen-containing heterocyclic ring by combining with R.sup.2; X is

two hydrogen atoms, an oxygen atom or a sulfur atom; {character pullout} is a single bond or a double bond, and Y is a nitrogen atom when {character pullout} is a double bond, or an oxygen atom, --N(R.sup.4)-- (in which R.sup.4 is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group) or S(O).sub.n (in which n is 0, 1 or 2) when {character pullout} is a single bond, or a salt thereof, which have somatostatin receptor agonistic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 30 OF 62 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
ACCESSION NUMBER: 2002:525863 SCISEARCH
THE GENUINE ARTICLE: 557XP
TITLE: **Glucagon-like peptide-1** (7-36)amide improves glucose utilisation and prevents the accumulation of pyruvate and lactate in the **ischemic** myocardium
AUTHOR: Gutniak M K (Reprint); Kavianipour M; Nystroem T; Ehlers M; Malmberg K; Ryden L; Wikstroem G
SOURCE: DIABETES, (JUN 2002) Vol. 51, Supp. [2], pp. A339-A339. MA 1386.
Publisher: AMER DIABETES ASSOC, 1660 DUKE ST, ALEXANDRIA, VA 22314 USA.
ISSN: 0012-1797.
DOCUMENT TYPE: Conference; Journal
LANGUAGE: English
REFERENCE COUNT: 0

L68 ANSWER 31 OF 62 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2002-18896 DRUGU T E
TITLE: **Glucagon-like peptide-1** (GLP-1) limits myocardial stunning following acute coronary occlusion and reperfusion in conscious canines.
AUTHOR: Nikolaidis L A; Hentosz T; Doverspike A; Huerbin R; Zourelias L; Stolarski C; Elahi D; Shannon R P
LOCATION: Pittsburgh, Pa.; Boston, Mass., USA
SOURCE: J.Am.Coll.Cardiol. (39, No. 5, Suppl. A, 312A, 2002) 1 Tab.
CODEN: JACCDI ISSN: 0735-1097
AVAIL. OF DOC.: Allegheny General Hospital, Pittsburgh, PA, U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature
AN 2002-18896 DRUGU T E
AB The effects of **glucagon-like peptide-1** (GLP-1) infusion were studied in a dog model of MI. Following 10 min coronary occlusion, dogs treated with GLP-1 1.5 pmol/kg/min for 24 hr showed less contractile dysfunction on reperfusion than placebo-treated dogs, despite comparable changes in coronary flow. The effects of GLP-1 were sustained for 24 hr. It is concluded that GLP-1 limits myocardial stunning and that GLP-1 may have therapeutic application in post-**ischemic** myocardial dysfunction. (conference abstract: American College of Cardiology, 51st Annual Scientific Session, Atlanta, Georgia, USA, 2002). (No EX).
ABEX (E33/JB)

L68 ANSWER 32 OF 62 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 2002075357 EMBASE
TITLE: Men at increased risk of coronary heart disease are not different from age- and weight-matched healthy controls in their postprandial triglyceride, nonesterified fatty acid, or incretin responses to sucrose.
AUTHOR: Brynes A.E.; Edwards C.M.; Ghatei M.A.; Bloom S.R.; Frost G.S.
CORPORATE SOURCE: Dr. G.S. Frost, Dept. of Nutrition and Dietetics,

Hammersmith Hospital, Du Cane Rd., London W12 0HS, United Kingdom

SOURCE: Metabolism: Clinical and Experimental, (2002) 51/2 (195-200).
Refs: 34
ISSN: 0026-0495 CODEN: METAAJ

COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
017 Public Health, Social Medicine and Epidemiology
003 Endocrinology
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Short-term studies suggest that extreme sucrose consumption has a detrimental effect on triglycerides (TG) in hypertriglyceridemic people. There is currently no consensus on the short-term inclusion of a moderate intake of sucrose in middle-aged men at increased risk of coronary heart disease (CHD). It is also unknown whether gut hormones that are released in response to carbohydrate ingestion modulate any of the effects of sucrose. The aim of this study was to further elucidate whether men at increased risk of CHD have an exaggerated response to sucrose compared with age- and weight-matched controls over an acute postprandial period. Twenty middle-aged men were recruited and separated into control (total cholesterol < 5.5mmol/L) and increased risk of CHD (> 5.5mmol/L) groups. We measured postprandial TG, nonesterified fatty acids (NEFA), insulin, glucose, **glucagon-like peptide-1** (GLP-1), and gastric inhibitory polypeptide (GIP) concentrations in response to a meal containing 75 g glucose or 75 g sucrose with a moderate fat load. The increased risk group had significantly higher Framingham risk assessment (12% v 4%), TG (2.4 .+-. 1.5 v 1.1 .+-. 0.4 mmol/L), low-density lipoprotein-cholesterol (LDL-C) (4.4 .+-. 0.5 v 2.7 .+-. 0.4 mmol/L), and lower high-density lipoprotein-cholesterol (HDL-C) (1.2 .+-. 0.2 v 1.5 .+-. 0.2 mmol/L) (P < .05 for all). There was no significant difference in the incremental area under the curve (IAUC, 0 to 360 minutes) for TG, NEFA, glucose, GLP-1, or GIP in response to glucose or sucrose within or between the groups. Absolute total area under the curve (not IAUC) for TG was significantly higher in the increased risk group for both glucose and sucrose, respectively (P = .01). A total of 75 g of sucrose given as part of a single meal appears to make little difference in the postprandial TG and NEFA response in men with or without risk of CHD compared with glucose. Although long-term data is needed, this begs the question whether a moderate intake of sucrose has been overemphasized as a detrimental dietary message in middle-aged men. Copyright .COPYRGT. 2002 by W.B. Saunders Company.

L68 ANSWER 33 OF 62 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2002-31846 DRUGU B P E
TITLE: **Glucagon-like peptide-1** (7-36) amide improves glucose utilisation and prevents the accumulation of pyruvate and lactate in the **ischemic** myocardium.
AUTHOR: Gutniak M K; Kavianipour M; Nystroem T; Ehlers M; Malmberg K; Ryden L; Wikstroem G
LOCATION: Stockholm, Umea; Uppsala, Swed.; Lincoln, Neb., USA
SOURCE: Diabetes (51, Suppl. 2, A339, 2002)
CODEN: DIAEAZ ISSN: 0012-1797
AVAIL. OF DOC.: No Reprint Address.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature
AN 2002-31846 DRUGU B P E
AB The effects of recombinant **glucagon-like peptide-1** (7-36) amide (GLP-1) infusion in MI were

studied in pigs. I.v. GLP-1 3 pmol/kg/min reduced tissue pyruvate and lactate in both **ischemic** and normal myocardium, increased plasma insulin and reduced blood glucose levels. GLP-1 did not affect hemodynamic parameters or the size of the MI. It is concluded that GLP-1 improves myocardial glucose utilization during ischemia with no adverse hemodynamic effects and may be therapeutically useful in diabetic patients with acute coronary syndromes. (conference abstract: 62nd Scientific Sessions of the American Diabetes Association, San Francisco, California, USA, 2002). (No EX).
ABEX (E33/JB)

L68 ANSWER 34 OF 62 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 7
ACCESSION NUMBER: 2001:510727 BIOSIS
DOCUMENT NUMBER: PREV200100510727
TITLE: Metabolic intervention with GLP-1 to improve the function of **ischemic** and **reperfused tissue**.
AUTHOR(S): Coolidge, Thomas R.; Ehlers, Mario R. W. (1)
CORPORATE SOURCE: (1) Lincoln, NE USA
ASSIGNEE: BioNebraska, Inc.
PATENT INFORMATION: US 6284725 September 04, 2001
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 4, 2001) Vol. 1250, No. 1, pp. No Pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the **glucagon-like peptide-1**. The invention relates to both the method and compositions for such treatment.

L68 ANSWER 35 OF 62 USPATFULL on STN DUPLICATE 8
ACCESSION NUMBER: 2001:119301 USPATFULL
TITLE: Methods of providing symptomatic and prophylactic neuroprotection
INVENTOR(S): Kozachuk, Walter E., Kensington, MD, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001009924	A1	20010726
	US 6515019	B2	20030204
APPLICATION INFO.:	US 2001-799051	A1	20010306 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-377866, filed on 20 Aug 1999, ABANDONED Continuation of Ser. No. US 1997-948319, filed on 10 Oct 1997, GRANTED, Pat. No. US 5942540 Continuation-in-part of Ser. No. US 1996-632338, filed on 10 Apr 1996, GRANTED, Pat. No. US 5728728
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MYERS, LINIAK & BERENATO, SUITE 240, 6550 ROCK SPRING DR., BETHESDA, MD, 20817
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are disclosed for prophylactically and chronically preventing symptomatic depression, neuronal cell injury and cell death in systemic and neurological conditions, populations with cerebrovascular risk factors, and invasive vascular procedures, employing a glycine-site antagonist at the NMDA (N-methyl-D-aspartate) complex e.g., 2-phenyl-1,3-propanediol dicarbamate (felbamate).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 36 OF 62 USPATFULL on STN

ACCESSION NUMBER:	2001:226644 USPATFULL			
TITLE:	Amine compounds, their production and use			
INVENTOR(S):	Suzuki, Nobuhiro, Tsukuba, Japan Kato, Kaneyoshi, Kawanishi, Japan Takekawa, Shiro, Tsukuba, Japan Terauchi, Jun, Ikeda, Japan Endo, Satoshi, Takatsuki, Japan			
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6329389	B1	20011211	
	WO 9952875		19991021	
APPLICATION INFO.:	US 1999-424285		19991119	(9)
	WO 1999-JP1871		19990408	
			19991119	PCT 371 date
			19991119	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1998-96422		19980408	
	JP 1998-345328		19981204	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Seaman, D. Margaret			
LEGAL REPRESENTATIVE:	Philippe Y. Riesen, Chao, Mark			
NUMBER OF CLAIMS:	28			
EXEMPLARY CLAIM:	1			
LINE COUNT:	6360			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a compound of the formula: ##STR1##

wherein Ar represents an aromatic group which may be substituted;

X represents methylene, S, SO, SO.sub.2 or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

i) R.sup.1 and R.sup.2 each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R.sup.1 and R.sup.2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

iii) R.sup.1 or R.sup.2 together with --(CH.sub.2).sub.n --N.dbd. form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;

Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,

with a proviso that X represents S, SO, SO.sub.2 or CO when Ring A has as a substituent a group represented by the formula:

--NHCOR.sup.11

where R.sup.11 represents alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula:

--NHR.sup.12

where R.sup.12 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof; which has an excellent somatostatin receptor binding inhibition action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 37 OF 62 USPATFULL on STN

ACCESSION NUMBER:	2001:226624 USPATFULL		
TITLE:	Fused 1,2,4-thiadiazine derivatives, their preparation and use		
INVENTOR(S):	Hansen, John Bondo, Jyderup, Denmark Nielsen, Flemming Elmelund, Virum, Denmark		
PATENT ASSIGNEE(S):	Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6329367	B1	20011211
APPLICATION INFO.:	US 1999-464979		19991216 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	DK 1998-1693		19981218
	DK 1999-18		19990111
	US 1999-115544P		19990112 (60)
	US 1999-116438P		19990120 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Truong, Tamthom N.		
LEGAL REPRESENTATIVE:	Green, Esq., Reza, Agris, Esq., Cheryl H.		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1111		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to 4H-thieno[3,2-e]-1,2,4-thiadiazine derivatives of the general formula: ##STR1##

wherein X, Y, R.sup.1, R.sup.2 and R.sup.3 are defined in the description, compositions thereof and methods for preparing the compounds are described.

The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 38 OF 62 USPATFULL on STN

ACCESSION NUMBER:	2001:168098 USPATFULL		
TITLE:	Methods of enhancing functioning of the large intestine		
INVENTOR(S):	Drucker, Daniel J., Ontario, Canada		
PATENT ASSIGNEE(S):	1149336 Ontario, Inc., Toronto, Canada (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6297214	B1	20011002

APPLICATION INFO.: US 1998-149831 19980908 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-850664, filed on 2 May 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dwayne C.
ASSISTANT EXAMINER: Delacruix-Muirheid, C.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 39 OF 62 USPATFULL on STN
ACCESSION NUMBER: 2001:71545 USPATFULL
TITLE: Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
INVENTOR(S): Hansen, Holger Claus, V.ae butted.rl.o slashed.se, Denmark
Tagmose, Tina M.o slashed.ller, Ballerup, Denmark
Hansen, John Bondo, Jyderup, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232310	B1	20010515
APPLICATION INFO.:	US 2000-520447		20000308 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-353	19990312
	US 1999-125883P	19990324 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: McKenzie, Thomas
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Rozek, Esq., Carol E.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to fused 1,4-thiazine-2-carbonitrile derivatives, compositions thereof and methods for preparing the compounds.

The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 40 OF 62 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2002-089892 [12] WPIDS

DOC. NO. CPI: C2002-027739
TITLE: New method of treating patients suffering from acute coronary syndrome, but not suffering from Q-wave myocardial infarction involves the use of **glucagon-like peptide-1** derivatives.
DERWENT CLASS: B04
INVENTOR(S): COOLIDGE, T R; EHLERS, M
PATENT ASSIGNEE(S): (BION-N) BIONEBRASKA INC; (COOL-I) COOLIDGE T R; (EHLE-I) EHLERS M
COUNTRY COUNT: 97
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001089554	A2	20011129	(200212)*	EN	38
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001063230	A	20011203	(200221)		
US 2002107206	A1	20020808	(200254)		
EP 1282436	A2	20030212	(200312)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
KR 2003001521	A	20030106	(200333)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2001089554	A2		WO 2001-US15996	20010518
AU 2001063230	A		AU 2001-63230	20010518
US 2002107206	A1	Provisional	US 2000-205239P	20000519
			US 2001-859804	20010518
EP 1282436	A2		EP 2001-937500	20010518
			WO 2001-US15996	20010518
KR 2003001521	A		KR 2002-715562	20021118

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001063230	A	Based on	WO 200189554
EP 1282436	A2	Based on	WO 200189554

PRIORITY APPLN. INFO: US 2000-205239P 20000519; US 2001-859804 20010518
AN 2002-089892 [12] WPIDS
AB WO 200189554 A UPAB: 20020221
NOVELTY - Treatment of patients suffering from acute coronary syndrome and not from Q-wave myocardial infarction (Q-wave MI) involves administering a **glucagon-like peptide-1** (GLP-1) molecule to the patients.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a kit comprising at least one dose of a GLP-1 molecule. The kit comprises a device selected from an insulin-type syringe, a pen injector that delivers a metered dose, a needle-less injector, a liquid-formulation, a dry-powder inhaler, a buccal-tablet or a sublingual tablet.

ACTIVITY - Cardiant; antianginal; vasotropic; antiemetic; analgesic; antidiabetic; hypotensive; antilipemic; anorectic; antiinflammatory; antiarrhythmic.

In a test carried out on Wistar rats, following reperfusion, the

coronary artery was reoccluded and Evans blue dye (4 ml) was injected into the left ventricle of the heart via a right carotid artery cannula. Evans Blue stains perfused myocardium, while occluded vascular bed remained uncolored. Animals were then killed by anesthetic overdose and the hearts were removed for examination. Hearts were sectioned and the right ventricular wall was removed. The area at risk (pink) was separated from the non-**ischemic** tissue. The area at risk was then cut into smaller pieces and stained with para-nitroblue tetrazolium (NBT) (0.5 mg/ml) for 20 minutes at 37 deg. C. In the presence of intact dehydrogenase enzyme system (viable myocardium), NBT formed a dark blue compound. Areas of necrosis lacked the enzyme and remained unstained. Tissue was separated to determined infarct size as a percentage of the area at risk. In rats receiving the saline infusion, the infarct size was 50 plus or minus 3%, in rats receiving the vehicle infusion, the infarct size was 46 1/4 and in rats receiving the GLP-1 infusion, the infarct size was 31 1/4. When compared to the vehicle, the infusion of GLP-1 caused a statistically significant reduction in infarct size of 33%. Thus, the systemic administration of GLP-1 could reduce myocardial infarct size when administered after occlusion of a coronary artery and prior to onset of reperfusion.

MECHANISM OF ACTION - GLP-1 receptor agonist.

USE - For treating patients suffering acute coronary syndrome without Q-wave myocardial infarction, stable and unstable angina, non-Q-wave cardiac necrosis, **ischemic** heart disease or at a risk of developing **ischemic** heart disease, cardiac abnormalities including congestive heart failure, worsening heart murmur due to mitral regurgitation and cardiac conduction disturbances; also for treating patients which have a blood troponin I level of less than 0.4 ng/ml and blood troponin T level of no more than 0.1 ng/ml; do not have elevated blood creatine kinase myocardial enzyme and ST-segment elevation and do not exhibit a pathological Q-wave and for treating those patients, which do not exhibit pain or exhibit symptoms such as chest pain greater than 15 minutes of duration, chest pain at rest or chest pain following minimal exertion that is poorly responsive to sublingual nitrates, nausea, shortness of breath, palpitation and dizziness and have not suffered from a Q-wave myocardial infarction prior to the onset of the symptoms, and having normal ECG; the compound is further useful for administration in performing angioplasty (all claimed). Also useful for treating patients showing symptoms of pulmonary edema and peripheral edema, artrial or ventricular extrasystoles, arterial fibrillation and other arrhythmias. Also for treating patients suffering from diabetes, hypertension, hypercholesterolemia, hyperlipidemia, obesity and smoking.

ADVANTAGE - The patient can administer GLP-1 to himself. The administration of GLP-1 following a Q-myocardial infarction (QMI) ameliorates the tissue damage that results from the QMI and subsequent reperfusion-induced injury. An advantage of using GLP-1 molecules is that high doses can be used without consequent hypoglycemia and hyperglycemia. Thus doses upto 10 nmol/kg can be used without adverse effects, as the action of the molecules are ideal for ideal for optimizing glucose metabolism in individuals including those with impaired glucose tolerance and elevated or aberrant blood glucose levels. The molecule increases the time during which thrombolytic therapy becomes effective following the first symptom of cardiac distress.

Dwg.0/0

L68 ANSWER 41 OF 62 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 2000:790326 CAPLUS

DOCUMENT NUMBER: 133:345167

TITLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the **ischemic** and reperfused brain

INVENTOR(S): Coolidge, Thomas R.; Ehlers, Mario R. W.

PATENT ASSIGNEE(S): Bionebraska, Inc., USA

SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066142	A2	20001109	WO 2000-US11652	20000501
WO 2000066142	A3	20020124		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6429197	B1	20020806	US 1999-303016	19990430
EP 1187628	A2	20020320	EP 2000-928616	20000501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543145	T2	20021217	JP 2000-615026	20000501
NO 2001005298	A	20011228	NO 2001-5298	20011029

PRIORITY APPLN. INFO.: US 1999-303016 A 19990430
US 1998-103498P P 19981008
WO 2000-US11652 W 20000501

AB It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably i.v. administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.

L68 ANSWER 42 OF 62 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2000:790323 CAPLUS
DOCUMENT NUMBER: 133:345166
TITLE: Metabolic intervention with GLP-1 to improve the function of **ischemic** and **reperfused tissue**
INVENTOR(S): Coolidge, Thomas R.; Ehlers, Mario R. W.
PATENT ASSIGNEE(S): Bionebraska, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066138	A2	20001109	WO 2000-US11251	20000427
WO 2000066138	A3	20010705		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6284725	B1	20010904	US 1999-302596	19990430
EP 1173197	A2	20020123	EP 2000-926404	20000427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

NZ 514610	A	20020927	NZ 2000-514610		20000427
JP 2002543142	T2	20021217	JP 2000-615022		20000427
NO 2001005294	A	20011228	NO 2001-5294		20011029
PRIORITY APPLN. INFO.:			US 1999-302596	A	19990430
			US 1998-103498P	P	19981008
			WO 2000-US11251	W	20000427

AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably i.v., with a compn. which includes a compd. which binds to a receptor for the **glucagon-like peptide-1**. The invention relates to both the method and compns. for such treatment.

L68 ANSWER 43 OF 62 USPATFULL on STN

ACCESSION NUMBER:	2000:37774 USPATFULL
TITLE:	Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
INVENTOR(S):	Dix, Thomas A., Mt. Pleasant, SC, United States
PATENT ASSIGNEE(S):	Medical University of South Carolina, Charleston, SC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6043218		20000328	
APPLICATION INFO.:	US 1996-736049		19961022	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Huff, Sheela
LEGAL REPRESENTATIVE:	Needle & Rosenberg, P.C.
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1
LINE COUNT:	1690

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 44 OF 62 COPYRIGHT 2003 Gale Group on STN DUPLICATE 11

ACCESSION NUMBER:	1999:233429 NLDB
TITLE:	OTHER NEWS TO NOTE.
SOURCE:	BIOWORLD Today, (14 Sep 1999) Vol. 10, No. 176.
PUBLISHER:	American Health Consultants, Inc.
DOCUMENT TYPE:	Newsletter
LANGUAGE:	English
WORD COUNT:	914

L68 ANSWER 45 OF 62 USPATFULL on STN

ACCESSION NUMBER:	1999:163409 USPATFULL
TITLE:	Functional expression of mammalian adenylyl cyclase in yeast
INVENTOR(S):	Broach, James R., Princeton, NJ, United States Manfredi, John P., Ossining, NY, United States Trueheart, Joshua, Nyack, NY, United States
PATENT ASSIGNEE(S):	Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6001553		19991214	
	WO 9530012		19951109	
APPLICATION INFO.:	US 1997-732218		19970114	(8)

WO 1995-US5149 19950426
19970114 PCT 371 date
19970114 PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-233700, filed on 26 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
LEGAL REPRESENTATIVE: Lahive & Cockfield LLP, DeConti, Jr., Giulio A., Lauro, Peter C.
NUMBER OF CLAIMS: 83
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 4954
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian adenylyl cyclases are functionally expressed in yeast cells. The yeast cells may be used to screen for inhibitors or activators of the adenylyl cyclase, or of a regulator of adenylyl cyclase which is functionally co-expressed in the yeast cell. Methods of identifying such inhibitors, activators and regulators are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 46 OF 62 USPATFULL on STN
ACCESSION NUMBER: 1999:99688 USPATFULL
TITLE: Methods of providing symptomatic and prophylactic neuroprotection
INVENTOR(S): Kozachuk, Walter E., 11403 Cam Ct., Kensington, MD, United States 20895-1313

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5942540		19990824
APPLICATION INFO.:	US 1997-948319		19971010 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-632338, filed on 10 Apr 1996, now patented, Pat. No. US 5728728
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Aulakh, Charanjit S.
LEGAL REPRESENTATIVE: Rhoa, Joseph A.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 481
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are disclosed for prophylactically and chronically preventing symptomatic depression, neuronal cell injury and cell death in systemic and neurological conditions, populations with cerebrovascular risk factors, and invasive vascular procedures, employing a glycine-site antagonist at the NMDA (N-methyl-D-aspartate) complex e.g., 2-phenyl-1,3-propanediol dicarbamate (felbamate).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 47 OF 62 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 1999:29164597 BIOTECHNO
TITLE: Effect of large bowel fermentation on insulin, glucose, free fatty acids, and **glucagon-like peptide 1** (7-36) amide in patients with coronary heart disease
AUTHOR: Frost G.; Brynes A.; Leeds A.
CORPORATE SOURCE: Dr. G. Frost, Nutrition and Dietetic Department, Hammersmith Hospital, London W12 OHS, United Kingdom.
SOURCE: Nutrition, (1999), 15/3 (183-188), 28 reference(s)

CODEN: NUTRER ISSN: 0899-9007
PUBLISHER ITEM IDENT.: S0899900798001774
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1999:29164597 BIOTECHNO
AB Insulin resistance syndrome has recently been described as a unifying hypothesis to explain the relationship between the many risk factors of coronary heart disease. Carbohydrate that is malabsorbed and fermented in the colon has been demonstrated to decrease insulin response to a glucose load and improve other risk factors associated with coronary heart disease, although the mechanism remains unclear. The object of the present study was to investigate whether this observation could be explained by the production of fermentation products induced by malabsorbed carbohydrate in the colon, or by stimulating the incretin glacagon-like peptide 1 (7-36) amide that is released from the large bowel. We used lactulose as a model for resistant starch carbohydrate. Ten insulin-resistant male volunteers, who had undergone previous coronary artery bypass grafting, volunteered to take part in the study and underwent 6 d of lactulose loading (15 g/d for 2 d and 30 g/d for 4 d). There was no significant change in insulin, glucose, free fatty acids, or **glucagon-like peptide 1** (7-36) amide response to an oral glucose tolerance test following the lactulose despite a significant rise in breath hydrogen. Large bowel fermentation stimulated by lactulose appears to have no significant effect on insulin, glucose, free fatty acids, and **glucagon-like peptide 1** (7-36) response in patients with coronary heart disease.

L68 ANSWER 48 OF 62 COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 97:71707 NLDB
TITLE: More H&Q Roundup
SOURCE: BioVenture View, (1 Mar 1997) Vol. 12, No. 3. ISSN: 0892-1903.
PUBLISHER: BioVenture Publishing
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 7012

L68 ANSWER 49 OF 62 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 97:113023 PROMT
TITLE: More H&Q Roundup
SOURCE: BioVenture View, (1 Mar 1997) pp. N/A. ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 7012
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB poor transfection efficiency,typically, not very much of the gene therapeutic ends up in the right cells, and not much gene expression is seen. Slanetz says that this actually has led to a safety problem,people try to use a very high dose of the plasmid payload, along with any contaminating proteins, to try and increase transfection, and they end up causing an immune reaction to the contaminants.
The next two years will be crucial as Transgene moves its products into Phase II clinicals. The company has about $30 million in the bank, which should get it another two years down the path, according to Slanetz. There are 170 employees and collaborations with a huge number of academic labs in the United States and Europe to move the science forward.
For more information, contact Dr. Slanetz at 617/871-2935 or Mr. Davitian at 011-33-3-88-27-91-21.
-Dr. Cynthia Robbins-Roth
Amylin Pharmaceuticals Inc.

(NASDAQ: AMLN)
Fighting Diabetes with Venom
Amylin Pharmaceuticals Inc. of San Diego, California, remains on track for a 1998 NDA filing for the company's diabetes drug candidate, pramlintide, according to president and CEO Richard Haugen. The company commenced the last four of six planned Phase III studies in December 1996. Together the six studies are aimed at demonstrating pramlintide's ability to improve long-term glucose control when used as an adjunct to insulin therapy in diabetics, thereby lowering their risk of degenerative complications from high blood glucose levels. Results of seven Phase II studies with pramlintide were promising, according to Haugen, showing a positive safety profile, no increase in hypoglycemia, and good integration of pramlintide with insulin dosing.
The results of the first two Phase III studies, begun in 1995, are expected by the third quarter of 1997. A preliminary look at three-month results by Amylin's development partner, Johnson & Johnson, was promising enough for that company to extend its collaboration with Amylin in August 1996. Enrollment should be completed for the four new studies in the third quarter, with results of the studies expected during 1998. Together the six studies will include data on 2,640 Type I and Type II diabetics gathered from more than 200 centers in the United States, Canada, and Europe. Amylin is also conducting long-term, open-label safety studies of pramlintide along with mechanism-of-action, insulin-mixing, and drug-interaction studies.
With pramlintide apparently headed toward commercialization, Amylin has begun broadening the company's pipeline. The company plans to in-license new products aggressively and sign an additional collaboration during 1997. Development is already progressing on two new product candidates: a peptide hormone related to diabetes and a novel protein derived from Gila monster venom.
The protein, called exendin, is homologous to human glucagon (48 percent sequence homology) and **glucagon-like peptide -1** (GLP-1, also known as insulinotropin), but it has a novel mechanism of action. Exendin lowers blood glucose significantly in animal models of diabetes and suppresses appetite in a dose-dependent manner. The company acquired rights to exendin in October 1996 from its discoverer, Dr. John Eng, a researcher at the Veterans Administration Medical Center in New York City.
That same month, Amylin also acquired worldwide rights to patents covering various uses of the GLP-1 hormone from Dr. John Dupre and the London Health Sciences Center at the University of Western Ontario, Canada. These patent applications cover the use of GLP-1's gastric emptying effects to control blood glucose in patients with Type I and Type II diabetes who use insulin. The company plans to evaluate use of GLP-1 both alone and in combination with Amylin's other product candidates, and it is continuing to support research in Dr. Dupre's laboratory.
Amylin has about $38 million in cash, which will support these efforts for about another 15 months.

L68 ANSWER 50 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36438 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom Q8, Q9 helodermin peptide SEQ ID NO:13.
AN AAB36438 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which

improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 51 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36437 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom helodermin peptide SEQ ID NO:12.
AN AAB36437 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 52 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36436 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom helospectin II peptide SEQ ID NO:11.
AN AAB36436 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 53 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36435 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom helospectin I peptide SEQ ID NO:10.
AN AAB36435 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 54 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36434 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W

PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom exendin 4 peptide SEQ ID NO:9.
AN AAB36434 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 55 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36433 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom exendin 4 peptide SEQ ID NO:8.
AN AAB36433 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 56 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36432 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: Gila monster venom exendin 3 peptide SEQ ID NO:7.
AN AAB36432 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a Gila monster venom peptide which is homologous to GLP-1, and is given in the exemplification of the present invention.

L68 ANSWER 57 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36431 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: **Glucagon-like peptide-1** derived peptide SEQ ID NO:6.
AN AAB36431 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and

reperfused tissues. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a GLP-1 peptide which is given in the exemplification of the present invention.

L68 ANSWER 58 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36430 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: **Glucagon-like peptide-1** derived peptide SEQ ID NO:5.

AN AAB36430 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a GLP-1 peptide which is given in the exemplification of the present invention.

L68 ANSWER 59 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36429 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: **Glucagon-like peptide-1** (7-36) SEQ ID NO:4.

AN AAB36429 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic

and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a GLP-1 peptide which is given in the exemplification of the present invention.

L68 ANSWER 60 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36428 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: **Glucagon-like peptide-1** (7-37) SEQ ID NO:3.
AN AAB36428 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a GLP-1 peptide which is given in the exemplification of the present invention.

L68 ANSWER 61 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36427 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: **Glucagon-like peptide-1** (1-36) SEQ ID NO:2.
AN AAB36427 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which

improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a GLP-1 peptide which is given in the exemplification of the present invention.

L68 ANSWER 62 OF 62 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAB36426 peptide DGENE
TITLE: Metabolic intervention with GLP-1 improves function of **ischemic** and **reperfused tissue** -
INVENTOR: Coolidge T R; Ehlers M R W
PATENT ASSIGNEE: (BION-N)BIONEBRASKA INC.
PATENT INFO: WO 2000066138 A2 20001109 22p
APPLICATION INFO: WO 2000-US11251 20000427
PRIORITY INFO: US 1999-302596 19990430
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-040881 [05]
DESCRIPTION: **Glucagon-like peptide-1** (1-37) SEQ ID NO:1.
AN AAB36426 peptide DGENE
AB The present invention describes metabolic intervention with GLP-1 which improves the function of ischaemic and **reperfused tissue**. The method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischaemia comprises administering a composition including a compound which binds to a receptor for **glucagon-like peptide-1** (GLP-1), in a carrier. Also described are: (1) a method of metabolic intervention with GLP-1 to improve the function of ischaemic and **reperfused tissue**, the method comprising administering a composition comprising GLP-1 in a carrier; and (2) a composition for use in the metabolic intervention with GLP-1 as above. The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischaemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischaemic and **reperfused tissues**. The method is devoid of side effects associated with current procedures. Antigenic and immune stimulating properties are not adversely affected. The present sequence represents a GLP-1 peptide which is given in the exemplification of the present invention.

=>

WEST Search History

DATE: Monday, August 18, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L4	ehlers-mario-r$-w$.in.	2	L4
L3	coolidge-thomas-r$.in.	22	L3
L2	glucagon adj like adj peptide-1 and (ischemic? or reperfused adj tissue)	6	L2
L1	glucagon adj like adj peptide-1 same (ischemic? or reperfused adj tissue)	1	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 6 of 6 returned.

1. Document ID: US 20030073626 A1

L2: Entry 1 of 6 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073626 A1

TITLE: Compositions and methods for treating peripheral vascular disease

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hathaway, David R.	Lincoln	NE	US	
Coolidge, Thomas R.	Falls Village	CT	US	

US-CL-CURRENT: 514/12; 424/722, 424/94.4, 514/18, 514/23, 514/419, 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

2. Document ID: US 20020147131 A1

L2: Entry 2 of 6 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147131
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147131 A1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario R.W.	Lincoln	NE	US	

US-CL-CURRENT: 514/2; 530/308

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

3. Document ID: US 20020055460 A1

L2: Entry 3 of 6 File: PGPB May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055460

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020055460 A1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario R.W.	Lincoln	NE	US	

US-CL-CURRENT: 514/2; 514/23, 514/53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

4. Document ID: US 6284725 B1

L2: Entry 4 of 6 File: USPT Sep 4, 2001

US-PAT-NO: 6284725
DOCUMENT-IDENTIFIER: US 6284725 B1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/2; 424/185.1, 514/12, 530/300, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

5. Document ID: US 20020055460 A1

L2: Entry 5 of 6 File: DWPI May 9, 2002

DERWENT-ACC-NO: 2002-470984
DERWENT-WEEK: 200250
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Method of metabolic intervention with glucagon-like peptide-1, useful for improving the function of ischemic and reperfused tissue, comprises administration with a carrier

INVENTOR: COOLIDGE, T R; EHLERS, M R W

PRIORITY-DATA: 1998US-103498P (October 8, 1998), 1999US-0302596 (April 30, 1999), 2001US-0851738 (May 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020055460 A1	May 9, 2002		008	A61K038/17

INT-CL (IPC): A61 K 31/70; A61 K 38/17

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

6. Document ID: JP 2002543142 W WO 200066138 A2 AU 200044935 A US 6284725 B1 EP 1173197 A2 NO 200105294 A US 20020055460 A1 CN 1349409 A NZ 514610 A US 20020147131 A1

L2: Entry 6 of 6 File: DWPI Dec 17, 2002

DERWENT-ACC-NO: 2001-040881
DERWENT-WEEK: 200312

TITLE: Metabolic intervention with GLP-1 improves function of ischemic and reperfused tissue

INVENTOR: COOLIDGE, T R; EHLERS, M R W

PRIORITY-DATA: 1999US-0302596 (April 30, 1999), 1998US-103498P (October 8, 1998), 2001US-0851738 (May 9, 2001), 2001US-0953021 (September 11, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002543142 W	December 17, 2002		026	A61K045/00
WO 200066138 A2	November 9, 2000	E	022	A61K038/00
AU 200044935 A	November 17, 2000		000	A61K038/00
US 6284725 B1	September 4, 2001		010	A61K038/00
EP 1173197 A2	January 23, 2002	E	000	A61K038/26
NO 200105294 A	December 28, 2001		000	C12Q000/00
US 20020055460 A1	May 9, 2002		008	A61K038/17
CN 1349409 A	May 15, 2002		000	A61K038/26
NZ 514610 A	September 27, 2002		000	A61K038/00
US 20020147131 A1	October 10, 2002		000	A61K038/28

INT-CL (IPC): A01 N 37/18; A01 N 38/17; A61 K 9/08; A61 K 9/70; A61 K 31/70; A61 K 38/00; A61 K 38/17; A61 K 38/26; A61 K 38/28; A61 K 45/00; A61 K 47/04; A61 K 47/06; A61 K 47/10; A61 K 47/18; A61 K 47/36; A61 P 9/10; A61 P 39/06; C07 K 5/00; C07 K 7/00; C07 K 16/00; C07 K 17/00; C12 Q 0/00; A61 K 31:7004; A61 K 38/26; A61 K 31:7004; A61 K 33:00; A61 K 38/26; A61 K 38/26; A61 K 38:44; A61 K 38/26; A61 K 38:06

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Term	Documents
GLUCAGON	5291
GLUCAGONS	85
LIKE	2458585
LIKES	4717
PEPTIDE-1	531
PEPTIDE-1S	0
REPERFUSED	773
REPERFUSEDS	0
TISSUE	284456
TISSUES	133957
(GLUCAGON ADJ LIKE ADJ PEPTIDE-1 AND (ISCHEMIC? OR REPERFUSED ADJ TISSUE)).USPT,PGPB,EPAB,DWPI,TDBD.	6

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US 20020055460 A1

L1: Entry 1 of 1 File: DWPI May 9, 2002

DERWENT-ACC-NO: 2002-470984
DERWENT-WEEK: 200250
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Method of metabolic intervention with glucagon-like peptide-1, useful for improving the function of ischemic and reperfused tissue, comprises administration with a carrier

INVENTOR: COOLIDGE, T R; EHLERS, M R W

PRIORITY-DATA: 1998US-103498P (October 8, 1998), 1999US-0302596 (April 30, 1999), 2001US-0851738 (May 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020055460 A1	May 9, 2002		008	A61K038/17

INT-CL (IPC): A61 K 31/70; A61 K 38/17

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Term	Documents
GLUCAGON	5291
GLUCAGONS	85
LIKE	2458585
LIKES	4717
PEPTIDE-1	531
PEPTIDE-1S	0
REPERFUSED	773
REPERFUSEDS	0
TISSUE	284456
TISSUES	133957
(GLUCAGON ADJ LIKE ADJ PEPTIDE-1 SAME (ISCHEMIC? OR REPERFUSED ADJ TISSUE)).USPT,PGPB,EPAB,DWPI,TDBD.	1

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 22 of 22 returned.

1. Document ID: US 20030073626 A1

L3: Entry 1 of 22 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073626 A1

TITLE: Compositions and methods for treating peripheral vascular disease

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hathaway, David R.	Lincoln	NE	US	
Coolidge, Thomas R.	Falls Village	CT	US	

US-CL-CURRENT: 514/12; 424/722, 424/94.4, 514/18, 514/23, 514/419, 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

2. Document ID: US 20020147131 A1

L3: Entry 2 of 22 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147131
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147131 A1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario R.W.	Lincoln	NE	US	

US-CL-CURRENT: 514/2; 530/308

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

3. Document ID: US 20020146405 A1

L3: Entry 3 of 22 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146405

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146405 A1

TITLE: Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario	Lincoln	NE	US	

US-CL-CURRENT: 424/94.61

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

4. Document ID: US 20020107206 A1

L3: Entry 4 of 22 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020107206
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020107206 A1

TITLE: Treatment of acute coronary syndrome with GLP-1

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario	Lincoln	NE	US	

US-CL-CURRENT: 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

5. Document ID: US 20020055460 A1

L3: Entry 5 of 22 File: PGPB May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055460
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020055460 A1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario R.W.	Lincoln	NE	US	

US-CL-CURRENT: 514/2; 514/23, 514/53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

6. Document ID: US 6429197 B1

L3: Entry 6 of 22 File: USPT Aug 6, 2002

US-PAT-NO: 6429197
DOCUMENT-IDENTIFIER: US 6429197 B1

TITLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/21; 424/185.1, 514/12, 514/2, 514/3, 530/303, 530/308, 530/324, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

7. Document ID: US 6284725 B1

L3: Entry 7 of 22 File: USPT Sep 4, 2001

US-PAT-NO: 6284725
DOCUMENT-IDENTIFIER: US 6284725 B1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/2; 424/185.1, 514/12, 530/300, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

8. Document ID: US 6127150 A

L3: Entry 8 of 22 File: USPT Oct 3, 2000

US-PAT-NO: 6127150
DOCUMENT-IDENTIFIER: US 6127150 A

TITLE: Purification cloning of peptides

DATE-ISSUED: October 3, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Wagner; Fred	Walton	NE		
van Heeke; Gino	Gainesville	FL		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
Wylie; Dwane E.	Lincoln	NE		

US-CL-CURRENT: 435/69.7; 435/195, 435/68.1, 435/69.4, 435/69.5, 435/70.1, 530/350, 530/351, 530/385, 530/399, 530/412, 530/415

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

9. Document ID: US 5741686 A

L3: Entry 9 of 22 File: USPT Apr 21, 1998

US-PAT-NO: 5741686
DOCUMENT-IDENTIFIER: US 5741686 A
**** See image for Certificate of Correction ****

TITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins

DATE-ISSUED: April 21, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Wylie; Dwane E.	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Lewis; William	Lincoln	NE		
Stout; Jay	Lincoln	NE		

US-CL-CURRENT: 435/188; 435/176, 435/177, 435/180, 435/181, 435/183, 435/41, 436/524, 436/528, 436/531, 436/532, 436/547 , 514/2, 530/402, 530/811, 530/812, 530/815, 530/816

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

10. Document ID: US 5700775 A

L3: Entry 10 of 22 File: USPT Dec 23, 1997

US-PAT-NO: 5700775
DOCUMENT-IDENTIFIER: US 5700775 A

TITLE: Method and treatment composition for decreasing patient time in catabolic state after traumatic injury

DATE-ISSUED: December 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gutniak; Mark K.	S-165 65 Hasselby			SE
Coolidge; Thomas R.	Falls Village	CT	06031	
Recker; Robert R.	Omaha	NE	68144	
Wagner; Fred W.	Walton	NE	68461	

US-CL-CURRENT: 514/12; 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

11. Document ID: US 5656456 A

L3: Entry 11 of 22 File: USPT Aug 12, 1997

US-PAT-NO: 5656456
DOCUMENT-IDENTIFIER: US 5656456 A
**** See image for Certificate of Correction ****

TITLE: Chemical method for selective modification of the N- and/or C-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stout; Jay	Lincoln	NE		
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Holmquist; Bart	Waltham	MA		

US-CL-CURRENT: 435/69.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

12. Document ID: US 5635371 A

L3: Entry 12 of 22 File: USPT Jun 3, 1997

US-PAT-NO: 5635371
DOCUMENT-IDENTIFIER: US 5635371 A
**** See image for Certificate of Correction ****

TITLE: Chemical method for selective modification of the N- and/or C-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stout; Jay	Lincoln	NE		
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Holmquist; Bart	Waltham	MA		

US-CL-CURRENT: 435/69.1

13. Document ID: US 5595887 A

L3: Entry 13 of 22 File: USPT Jan 21, 1997

US-PAT-NO: 5595887
DOCUMENT-IDENTIFIER: US 5595887 A
**** See image for Certificate of Correction ****

TITLE: Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment

DATE-ISSUED: January 21, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Wagner; Fred	Walton	NE		
van Heeke; Gino	Gainesville	FL		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
Wylie; Dwane E.	Lincoln	NE		

US-CL-CURRENT: 435/69.7; 435/68.1

14. Document ID: US 5464759 A

L3: Entry 14 of 22 File: USPT Nov 7, 1995

US-PAT-NO: 5464759
DOCUMENT-IDENTIFIER: US 5464759 A

TITLE: Sequential oligonucleotide syntheses using immunoaffinity techniques

DATE-ISSUED: November 7, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Lewis; William	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
van Heeke; Gino	Gainesville	FL		
Wylie; Dwane	Lincoln	NE		
Wagner; Fred W.	Walton	NE		

US-CL-CURRENT: 435/91.2; 435/6, 514/44, 536/22.1, 536/23.1, 536/24.1, 536/24.2, 536/24.31, 536/24.32, 536/25.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

15. Document ID: US 5279954 A

L3: Entry 15 of 22 File: USPT Jan 18, 1994

US-PAT-NO: 5279954
DOCUMENT-IDENTIFIER: US 5279954 A

TITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins

DATE-ISSUED: January 18, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Wylie; Dwane E.	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Lewis; William	Lincoln	NE		
Stout; Jay	Lincoln	NE		

US-CL-CURRENT: 435/176; 435/177, 435/180, 435/181, 436/524, 436/528, 436/531, 436/532, 530/811, 530/812, 530/815, 530/816

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

16. Document ID: US 5234820 A

L3: Entry 16 of 22 File: USPT Aug 10, 1993

US-PAT-NO: 5234820
DOCUMENT-IDENTIFIER: US 5234820 A

TITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins

DATE-ISSUED: August 10, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
Wylie; Dwane E.	Lincoln	NE		
Breddam; Klaus	Glostrup			DK
Lewis; William	Lincoln	NE		

US-CL-CURRENT: 435/41; 435/181, 435/7.1, 435/7.92, 436/532, 436/544, 530/816

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

17. Document ID: US 5221736 A

L3: Entry 17 of 22 File: USPT Jun 22, 1993

US-PAT-NO: 5221736
DOCUMENT-IDENTIFIER: US 5221736 A
**** See image for Certificate of Correction ****

TITLE: Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques

DATE-ISSUED: June 22, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Lewis; William	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Wylie; Dwane	Lincoln	NE		
Wagner; Fred W.	Walton	NE		
Stout; Jay	Lincoln	NE		
van Heeke; Gino	Gainesville	FL		

US-CL-CURRENT: 536/25.31; 435/4, 435/5, 435/6, 435/7.5, 435/7.8, 435/803, 435/810, 435/91.5, 436/518, 436/531, 436/824, 530/387.1, 536/26.71

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

18. Document ID: EP 1170300 A1

L3: Entry 18 of 22 File: EPAB Jan 9, 2002

PUB-NO: EP001170300A1
DOCUMENT-IDENTIFIER: EP 1170300 A1
TITLE: Method for modification of recombinant polypeptides

PUBN-DATE: January 9, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
STOUT, JAY	US
WAGNER, FRED W	US
COOLIDGE, THOMAS R	US
HOLMQUIST, BART	US

INT-CL (IPC): C07 K 1/00; C07 K 1/06

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

19. Document ID: WO 9947161 A1

L3: Entry 19 of 22 File: EPAB Sep 23, 1999

PUB-NO: WO009947161A1

DOCUMENT-IDENTIFIER: WO 9947161 A1
TITLE: HUMAN APPETITE CONTROL BY GLUCAGON-LIKE PEPTIDE RECEPTOR BINDING COMPOUNDS

PUBN-DATE: September 23, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
GOKE, BURKHARD	DE
BEGLINGER, CHRISTOPH	CH
COOLIDGE, THOMAS R	US

INT-CL (IPC): A61 K 38/26; C07 K 14/605
EUR-CL (EPC): C07K014/605; A61K038/26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

20. Document ID: WO 9503321 A1

L3: Entry 20 of 22 File: EPAB Feb 2, 1995

PUB-NO: WO009503321A1
DOCUMENT-IDENTIFIER: WO 9503321 A1
TITLE: METHOD FOR ENDOMODIFICATION OF PROTEINS

PUBN-DATE: February 2, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
WAGNER, FRED W	
COOLIDGE, THOMAS R	

INT-CL (IPC): C07 K 1/13; C07 K 1/00; C07 K 1/107; C12 P 21/02
EUR-CL (EPC): C07K001/00; C07K001/107, C07K001/107 , C07K001/13 , C12P021/02

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

21. Document ID: WO 9401451 A2

L3: Entry 21 of 22 File: EPAB Jan 20, 1994

PUB-NO: WO009401451A2
DOCUMENT-IDENTIFIER: WO 9401451 A2
TITLE: METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES

PUBN-DATE: January 20, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
STOUT, JAY	
WAGNER, FRED W	
COOLIDGE, THOMAS R	
HOLMQUIST, BART	

INT-CL (IPC): C07K 1/00; C07K 3/08
EUR-CL (EPC): C07K001/107; C07K001/107, C07K005/10 , C07K007/18 , C07K014/47 , C07K014/475 , C07K001/00 , C07K001/00 , C07K001/12 , C12N015/62

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

22. Document ID: WO 9010709 A2

L3: Entry 22 of 22 File: EPAB Sep 20, 1990

PUB-NO: WO009010709A2
DOCUMENT-IDENTIFIER: WO 9010709 A2
TITLE: MONOCLONAL ANTIBODIES FOR SMALL MOIETIES, METHODS THEREFOR

PUBN-DATE: September 20, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
WAGNER, FRED W	US
WYLIE, DWANE E	US
SCHUSTER, SHELDON M	US
COOLIDGE, THOMAS R	US
SONG, PILL-SOON	US
PARKER, WILLIAM	US

US-CL-CURRENT: 435/7.92; 435/332, 435/FOR.111, 530/388.9
INT-CL (IPC): C12N 5/16; C12P 21/08; G01N 33/53; G01N 33/577
EUR-CL (EPC): G01N033/68; G01N033/84, G01N033/543 , C07K016/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Clip Img | Image

Generate Collection | Print

Term	Documents
COOLIDGE-THOMAS-R$	0
COOLIDGE-THOMAS-R	22
COOLIDGE-THOMAS-R$.IN..USPT,PGPB,EPAB,DWPI,TDBD.	22
(COOLIDGE-THOMAS-R$.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	22

Display Format: Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 22 of 22 returned.

1. Document ID: US 20030073626 A1

L3: Entry 1 of 22 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073626 A1

TITLE: Compositions and methods for treating peripheral vascular disease

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hathaway, David R.	Lincoln	NE	US	
Coolidge, Thomas R.	Falls Village	CT	US	

US-CL-CURRENT: 514/12; 424/722, 424/94.4, 514/18, 514/23, 514/419, 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

2. Document ID: US 20020147131 A1

L3: Entry 2 of 22 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147131
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147131 A1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario R.W.	Lincoln	NE	US	

US-CL-CURRENT: 514/2; 530/308

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

3. Document ID: US 20020146405 A1

L3: Entry 3 of 22 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146405

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146405 A1

TITLE: Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario	Lincoln	NE	US	

US-CL-CURRENT: 424/94.61

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

4. Document ID: US 20020107206 A1

L3: Entry 4 of 22 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020107206
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020107206 A1

TITLE: Treatment of acute coronary syndrome with GLP-1

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario	Lincoln	NE	US	

US-CL-CURRENT: 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

5. Document ID: US 20020055460 A1

L3: Entry 5 of 22 File: PGPB May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055460
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020055460 A1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario R.W.	Lincoln	NE	US	

US-CL-CURRENT: 514/2; 514/23, 514/53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

6. Document ID: US 6429197 B1

L3: Entry 6 of 22 File: USPT Aug 6, 2002

US-PAT-NO: 6429197
DOCUMENT-IDENTIFIER: US 6429197 B1

TITLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/21; 424/185.1, 514/12, 514/2, 514/3, 530/303, 530/308, 530/324, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

7. Document ID: US 6284725 B1

L3: Entry 7 of 22 File: USPT Sep 4, 2001

US-PAT-NO: 6284725
DOCUMENT-IDENTIFIER: US 6284725 B1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/2; 424/185.1, 514/12, 530/300, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

8. Document ID: US 6127150 A

L3: Entry 8 of 22 File: USPT Oct 3, 2000

US-PAT-NO: 6127150
DOCUMENT-IDENTIFIER: US 6127150 A

TITLE: Purification cloning of peptides

DATE-ISSUED: October 3, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Wagner; Fred	Walton	NE		
van Heeke; Gino	Gainesville	FL		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
Wylie; Dwane E.	Lincoln	NE		

US-CL-CURRENT: 435/69.7; 435/195, 435/68.1, 435/69.4, 435/69.5, 435/70.1, 530/350, 530/351, 530/385, 530/399, 530/412, 530/415

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

9. Document ID: US 5741686 A

L3: Entry 9 of 22 File: USPT Apr 21, 1998

US-PAT-NO: 5741686
DOCUMENT-IDENTIFIER: US 5741686 A
**** See image for Certificate of Correction ****

TITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins

DATE-ISSUED: April 21, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Wylie; Dwane E.	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Lewis; William	Lincoln	NE		
Stout; Jay	Lincoln	NE		

US-CL-CURRENT: 435/188; 435/176, 435/177, 435/180, 435/181, 435/183, 435/41, 436/524, 436/528, 436/531, 436/532, 436/547 , 514/2, 530/402, 530/811, 530/812, 530/815, 530/816

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

10. Document ID: US 5700775 A

L3: Entry 10 of 22 File: USPT Dec 23, 1997

US-PAT-NO: 5700775
DOCUMENT-IDENTIFIER: US 5700775 A

TITLE: Method and treatment composition for decreasing patient time in catabolic state after traumatic injury

DATE-ISSUED: December 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gutniak; Mark K.	S-165 65 Hasselby			SE
Coolidge; Thomas R.	Falls Village	CT	06031	
Recker; Robert R.	Omaha	NE	68144	
Wagner; Fred W.	Walton	NE	68461	

US-CL-CURRENT: 514/12; 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

11. Document ID: US 5656456 A

L3: Entry 11 of 22 File: USPT Aug 12, 1997

US-PAT-NO: 5656456
DOCUMENT-IDENTIFIER: US 5656456 A
**** See image for Certificate of Correction ****

TITLE: Chemical method for selective modification of the N- and/or C-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stout; Jay	Lincoln	NE		
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Holmquist; Bart	Waltham	MA		

US-CL-CURRENT: 435/69.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

12. Document ID: US 5635371 A

L3: Entry 12 of 22 File: USPT Jun 3, 1997

US-PAT-NO: 5635371
DOCUMENT-IDENTIFIER: US 5635371 A
**** See image for Certificate of Correction ****

TITLE: Chemical method for selective modification of the N- and/or C-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stout; Jay	Lincoln	NE		
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Holmquist; Bart	Waltham	MA		

US-CL-CURRENT: 435/69.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

13. Document ID: US 5595887 A

L3: Entry 13 of 22 File: USPT Jan 21, 1997

US-PAT-NO: 5595887
DOCUMENT-IDENTIFIER: US 5595887 A
**** See image for Certificate of Correction ****

TITLE: Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment

DATE-ISSUED: January 21, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Wagner; Fred	Walton	NE		
van Heeke; Gino	Gainesville	FL		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
Wylie; Dwane E.	Lincoln	NE		

US-CL-CURRENT: 435/69.7; 435/68.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

14. Document ID: US 5464759 A

L3: Entry 14 of 22 File: USPT Nov 7, 1995

US-PAT-NO: 5464759
DOCUMENT-IDENTIFIER: US 5464759 A

TITLE: Sequential oligonucleotide syntheses using immunoaffinity techniques

DATE-ISSUED: November 7, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Lewis; William	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
van Heeke; Gino	Gainesville	FL		
Wylie; Dwane	Lincoln	NE		
Wagner; Fred W.	Walton	NE		

US-CL-CURRENT: 435/91.2; 435/6, 514/44, 536/22.1, 536/23.1, 536/24.1, 536/24.2, 536/24.31, 536/24.32, 536/25.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Draw Desc | Image

15. Document ID: US 5279954 A

L3: Entry 15 of 22 File: USPT Jan 18, 1994

US-PAT-NO: 5279954
DOCUMENT-IDENTIFIER: US 5279954 A

TITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins

DATE-ISSUED: January 18, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Wylie; Dwane E.	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Lewis; William	Lincoln	NE		
Stout; Jay	Lincoln	NE		

US-CL-CURRENT: 435/176; 435/177, 435/180, 435/181, 436/524, 436/528, 436/531, 436/532, 530/811, 530/812, 530/815, 530/816

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Draw Desc | Image

16. Document ID: US 5234820 A

L3: Entry 16 of 22 File: USPT Aug 10, 1993

US-PAT-NO: 5234820
DOCUMENT-IDENTIFIER: US 5234820 A

TITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins

DATE-ISSUED: August 10, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Fred W.	Walton	NE		
Coolidge; Thomas R.	Falls Village	CT		
Schuster; Sheldon M.	Gainesville	FL		
Stout; Jay	Lincoln	NE		
Wylie; Dwane E.	Lincoln	NE		
Breddam; Klaus	Glostrup			DK
Lewis; William	Lincoln	NE		

US-CL-CURRENT: 435/41; 435/181, 435/7.1, 435/7.92, 436/532, 436/544, 530/816

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Draw Desc | Image

17. Document ID: US 5221736 A

L3: Entry 17 of 22 File: USPT Jun 22, 1993

US-PAT-NO: 5221736
DOCUMENT-IDENTIFIER: US 5221736 A
**** See image for Certificate of Correction ****

TITLE: Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques

DATE-ISSUED: June 22, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Lewis; William	Lincoln	NE		
Schuster; Sheldon M.	Gainesville	FL		
Wylie; Dwane	Lincoln	NE		
Wagner; Fred W.	Walton	NE		
Stout; Jay	Lincoln	NE		
van Heeke; Gino	Gainesville	FL		

US-CL-CURRENT: 536/25.31; 435/4, 435/5, 435/6, 435/7.5, 435/7.8, 435/803, 435/810, 435/91.5, 436/518, 436/531, 436/824, 530/387.1, 536/26.71

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

18. Document ID: EP 1170300 A1

L3: Entry 18 of 22 File: EPAB Jan 9, 2002

PUB-NO: EP001170300A1
DOCUMENT-IDENTIFIER: EP 1170300 A1
TITLE: Method for modification of recombinant polypeptides

PUBN-DATE: January 9, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
STOUT, JAY	US
WAGNER, FRED W	US
COOLIDGE, THOMAS R	US
HOLMQUIST, BART	US

INT-CL (IPC): C07 K 1/00; C07 K 1/06

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

19. Document ID: WO 9947161 A1

L3: Entry 19 of 22 File: EPAB Sep 23, 1999

PUB-NO: WO009947161A1

DOCUMENT-IDENTIFIER: WO 9947161 A1
TITLE: HUMAN APPETITE CONTROL BY GLUCAGON-LIKE PEPTIDE RECEPTOR BINDING COMPOUNDS

PUBN-DATE: September 23, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
GOKE, BURKHARD	DE
BEGLINGER, CHRISTOPH	CH
COOLIDGE, THOMAS R	US

INT-CL (IPC): A61 K 38/26; C07 K 14/605
EUR-CL (EPC): C07K014/605; A61K038/26

Full | Title | Citation | Front | Reverse | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

20. Document ID: WO 9503321 A1

L3: Entry 20 of 22 File: EPAB Feb 2, 1995

PUB-NO: WO009503321A1
DOCUMENT-IDENTIFIER: WO 9503321 A1
TITLE: METHOD FOR ENDOMODIFICATION OF PROTEINS

PUBN-DATE: February 2, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
WAGNER, FRED W	
COOLIDGE, THOMAS R	

INT-CL (IPC): C07 K 1/13; C07 K 1/00; C07 K 1/107; C12 P 21/02
EUR-CL (EPC): C07K001/00; C07K001/107, C07K001/107 , C07K001/13 , C12P021/02

Full | Title | Citation | Front | Reverse | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

21. Document ID: WO 9401451 A2

L3: Entry 21 of 22 File: EPAB Jan 20, 1994

PUB-NO: WO009401451A2
DOCUMENT-IDENTIFIER: WO 9401451 A2
TITLE: METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES

PUBN-DATE: January 20, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
STOUT, JAY	
WAGNER, FRED W	
COOLIDGE, THOMAS R	
HOLMQUIST, BART	

INT-CL (IPC): C07K 1/00; C07K 3/08
EUR-CL (EPC): C07K001/107; C07K001/107, C07K005/10 , C07K007/18 , C07K014/47 , C07K014/475 , C07K001/00 , C07K001/00 , C07K001/12 , C12N015/62

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

22. Document ID: WO 9010709 A2

L3: Entry 22 of 22 File: EPAB Sep 20, 1990

PUB-NO: WO009010709A2
DOCUMENT-IDENTIFIER: WO 9010709 A2
TITLE: MONOCLONAL ANTIBODIES FOR SMALL MOIETIES, METHODS THEREFOR

PUBN-DATE: September 20, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
WAGNER, FRED W	US
WYLIE, DWANE E	US
SCHUSTER, SHELDON M	US
COOLIDGE, THOMAS R	US
SONG, PILL-SOON	US
PARKER, WILLIAM	US

US-CL-CURRENT: 435/7.92; 435/332, 435/FOR.111, 530/388.9
INT-CL (IPC): C12N 5/16; C12P 21/08; G01N 33/53; G01N 33/577
EUR-CL (EPC): G01N033/68; G01N033/84, G01N033/543 , C07K016/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Clip Img | Image

Generate Collection | Print

Term	Documents
COOLIDGE-THOMAS-R$	0
COOLIDGE-THOMAS-R	22
COOLIDGE-THOMAS-R$.IN..USPT,PGPB,EPAB,DWPI,TDBD.	22
(COOLIDGE-THOMAS-R$.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	22

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

1. Document ID: US 6429197 B1

L4: Entry 1 of 2 File: USPT Aug 6, 2002

US-PAT-NO: 6429197
DOCUMENT-IDENTIFIER: US 6429197 B1

TITLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/21; 424/185.1, 514/12, 514/2, 514/3, 530/303, 530/308, 530/324, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

2. Document ID: US 6284725 B1

L4: Entry 2 of 2 File: USPT Sep 4, 2001

US-PAT-NO: 6284725
DOCUMENT-IDENTIFIER: US 6284725 B1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coolidge; Thomas R.	Falls Village	CT		
Ehlers; Mario R. W.	Lincoln	NE		

US-CL-CURRENT: 514/2; 424/185.1, 514/12, 530/300, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Term	Documents
EHLERS-MARIO-R$-W$	0
EHLERS-MARIO-R-W	2
EHLERS-MARIO-R$-W$.IN..USPT,PGPB,EPAB,DWPI,TDBD.	2
(EHLERS-MARIO-R$-W$.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	2

Display Format: - Change Format

Previous Page Next Page

WEST Search History

DATE: Monday, August 18, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
L5	glucagon adj like adj peptide-1 same pharmaceutical adj composition	25	L5
L4	ehlers-mario-r$-w$.in.	2	L4
L3	coolidge-thomas-r$.in.	22	L3
L2	glucagon adj like adj peptide-1 and (ischemic? or reperfused adj tissue)	6	L2
L1	glucagon adj like adj peptide-1 same (ischemic? or reperfused adj tissue)	1	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 25 of 25 returned.

1. Document ID: US 20030139429 A1

L5: Entry 1 of 25 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139429
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030139429 A1

TITLE: Combinations

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cohen, David Saul	New Providence	NJ	US	

US-CL-CURRENT: 514/263.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

2. Document ID: US 20030125334 A1

L5: Entry 2 of 25 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030125334
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030125334 A1

TITLE: 5-HT receptor ligands and uses thereof

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chiang, Phoebe	East Lyme	CT	US	
Novomisle, William A.	Stonington	CT	US	
Welch, Willard M. JR.	Mystic	CT	US	
Guzman-Perez, Angel	Stonington	CT	US	
DaSilva-Jardine, Paul A.	Killingworth	CT	US	
Garigipati, Ravi S.	South Glastonbury	CT	US	
Liu, Kevin K.	East Lyme	CT	US	

US-CL-CURRENT: 514/252.11; 544/357

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

3. Document ID: US 20030114469 A1

L5: Entry 3 of 25 File: PGPB Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030114469
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030114469 A1

TITLE: Combinations

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cohen, David Saul	New Providence	NJ	US	

US-CL-CURRENT: 514/263.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

4. Document ID: US 20030105106 A1

L5: Entry 4 of 25 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030105106
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030105106 A1

TITLE: 5-HT receptor ligands and uses thereof

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chiang, Phoebe	East Lyme	CT	US	
Novomisle, William A.	Stonington	CT	US	
Welch, Willard M. JR.	Mystic	CT	US	

US-CL-CURRENT: 514/252.11; 514/252.14, 544/295, 544/357

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

5. Document ID: US 20030073728 A1

L5: Entry 5 of 25 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073728
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073728 A1

TITLE: Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
van Poelje, Paul D.	La Jolla	CA	US	
Erion, Mark D.	Del Mar	CA	US	
Fujiwara, Toshihiko			US	

US-CL-CURRENT: 514/369; 514/592

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

6. Document ID: US 20030072822 A1

L5: Entry 6 of 25 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030072822
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030072822 A1

TITLE: Methods for treating disorders using plant extracts

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ribnicky, David M.	Plainsboro	NJ	US	
Raskin, Ilya	Manalapan	NJ	US	

US-CL-CURRENT: 424/740

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

7. Document ID: US 20030040516 A1

L5: Entry 7 of 25 File: PGPB Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040516
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040516 A1

TITLE: Pyrazinone inhibitors of fatty acid binding protein and method

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sulsky, Richard	West Trenton	NJ	US	
Robl, Jeffrey A.	Newtown	PA	US	

US-CL-CURRENT: 514/247; 514/252.01, 514/252.03, 514/252.05, 544/238, 544/239

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

8. Document ID: US 20020165148 A1

L5: Entry 8 of 25 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165148
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165148 A1

TITLE: Analogues and derivatives of gastrin releasing peptide (GRP)

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Per Franklin	Vaerlose		DK	
Ribel-Madsen, Ulla	Virum		DK	
Wagtmann, Peter Andreas Nicolai Reumert	Rungsted Kyst		DK	

US-CL-CURRENT: 514/12; 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

9. Document ID: US 20020025933 A1

L5: Entry 9 of 25 File: PGPB Feb 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020025933
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020025933 A1

TITLE: GLP-2 derivatives

PUBLICATION-DATE: February 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knudsen, Liselotte Bjerre	Valby		DK	
Huusfeldt, Per Olaf	Kobenhavn K		DK	
Nielsen, Per Franklin	Vaerlose		DK	
Kaarsholm, Niels C.	Vanlose		DK	
Olsen, Helle Birk	Allerod		DK	
Thim, Lars	Gentofte		DK	
Bjorn, Soren Erik	Lyngby		DK	

US-CL-CURRENT: 514/12; 530/397

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

10. Document ID: US 20010047084 A1

L5: Entry 10 of 25 File: PGPB Nov 29, 2001

PGPUB-DOCUMENT-NUMBER: 20010047084
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010047084 A1

TITLE: Extendin derivatives

PUBLICATION-DATE: November 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knudsen, Liselotte Bjerre	Valby		DK	
Huusfeldt, Per Olaf	Copenhagen K		DK	
Nielsen, Per Franklin	Vaerlose		DK	
Madsen, Kjeld	Vaerlose		DK	

US-CL-CURRENT: 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

11. Document ID: US 20010046956 A1

L5: Entry 11 of 25 File: PGPB Nov 29, 2001

PGPUB-DOCUMENT-NUMBER: 20010046956
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010046956 A1

TITLE: Methods of treating obesity using a neurotensin receptor ligand

PUBLICATION-DATE: November 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hadcock, John R.	East Lyme	CT	US	

US-CL-CURRENT: 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

12. Document ID: US 20010011071 A1

L5: Entry 12 of 25 File: PGPB Aug 2, 2001

PGPUB-DOCUMENT-NUMBER: 20010011071
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010011071 A1

TITLE: DERIVATIVES OF GLP-1 ANALOGS

PUBLICATION-DATE: August 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
KNUDSEN, LISELOTTE BJERRE	VALBY		DK	
HUUSFELDT, PER OLAF	KOBENHAVN K		DK	
NIELSEN, PER FRANKLIN	VARLOSE		DK	
KAARSHOLM, NIELS C.	VANLOSE		DK	
OLSEN, HELLE BIRK	ALLEROD		DK	
BJORN, SOREN ERIK	LYNGBY		DK	
PEDERSEN, FREDDY ZIMMERDAHL	VARLOSE		DK	
MADSEN, KJELD	VARLOSE		DK	

US-CL-CURRENT: 514/12; 530/308

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

13. Document ID: US 6583111 B1

L5: Entry 13 of 25 File: USPT Jun 24, 2003

US-PAT-NO: 6583111
DOCUMENT-IDENTIFIER: US 6583111 B1

TITLE: Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity

DATE-ISSUED: June 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
DiMarchi; Richard	Carmel	IN		
Efendic; Suad	Lidingo			SE

US-CL-CURRENT: 514/2; 514/12, 514/866, 530/300

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

14. Document ID: US 6518241 B2

L5: Entry 14 of 25 File: USPT Feb 11, 2003

US-PAT-NO: 6518241
DOCUMENT-IDENTIFIER: US 6518241 B2

TITLE: Shock heat treatment of polypeptides

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matthiesen; Finn	Bronshoj			DK

US-CL-CURRENT: 514/2; 435/69.1, 514/12, 514/13, 514/14, 530/303, 530/308, 530/324, 530/350, 530/365, 530/366

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

15. Document ID: US 6458924 B2

L5: Entry 15 of 25 File: USPT Oct 1, 2002

US-PAT-NO: 6458924
DOCUMENT-IDENTIFIER: US 6458924 B2

TITLE: Derivatives of GLP-1 analogs

DATE-ISSUED: October 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Knudsen; Liselotte Bjerre	Valby			DK
Huusfeldt; Per Olaf	K.o slashed.benhavn K			DK
Nielsen; Per Franklin	V.ae butted.rl.o slashed.se			DK

US-CL-CURRENT: 530/324; 530/345

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DwMC | Draw Desc | Image

16. Document ID: US 6348447 B1

L5: Entry 16 of 25 File: USPT Feb 19, 2002

US-PAT-NO: 6348447
DOCUMENT-IDENTIFIER: US 6348447 B1

TITLE: Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hellstrom; Per	16775 Bromma			SE
Efendic; Suad	18134 Lidingo			SE

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/324, 530/325, 530/326, 530/327

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DwMC | Draw Desc | Image

17. Document ID: US 6268343 B1

L5: Entry 17 of 25 File: USPT Jul 31, 2001

US-PAT-NO: 6268343
DOCUMENT-IDENTIFIER: US 6268343 B1

TITLE: Derivatives of GLP-1 analogs

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Knudsen; Liselotte Bjerre	Valby			DK
Huusfeldt; Per Olaf	K.o slashed.benhavn K			DK
Nielsen; Per Franklin	V.ae butted.rl.o slashed.se			DK
Kaarsholm; Niels C.	Vanl.o slashed.se			DK
Olsen; Helle Birk	Aller.o slashed.d			DK
Bj.o slashed.rn; S.o slashed.ren Erik	Lyngby			DK
Pedersen; Freddy Zimmerdahl	V.ae butted.rl.o slashed.se			DK
Madsen; Kjeld	V.ae butted.rl.o slashed.se			DK

US-CL-CURRENT: 514/12; 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

18. Document ID: US 6191102 B1

L5: Entry 18 of 25 File: USPT Feb 20, 2001

US-PAT-NO: 6191102
DOCUMENT-IDENTIFIER: US 6191102 B1
**** See image for Certificate of Correction ****

TITLE: Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity

DATE-ISSUED: February 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
DiMarchi; Richard D.	Carmel	IN		
Efendic; Suad	Lidingo			SE

US-CL-CURRENT: 514/2; 514/12, 514/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

19. Document ID: WO 9964060 A1

L5: Entry 19 of 25 File: EPAB Dec 16, 1999

PUB-NO: WO009964060A1
DOCUMENT-IDENTIFIER: WO 9964060 A1
TITLE: PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME AND NEW USE OF SUBSTANCES THEREIN

PUBN-DATE: December 16, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
HELLSTROEM, PER	SE
EFENDIC, SUAD	SE

INT-CL (IPC): A61 K 38/26; A61 K 38/31
EUR-CL (EPC): A61K038/31; A61K038/26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

20. Document ID: WO 9943707 A1

L5: Entry 20 of 25 File: EPAB Sep 2, 1999

PUB-NO: WO009943707A1
DOCUMENT-IDENTIFIER: WO 9943707 A1
TITLE: N-TERMINALLY MODIFIED GLP-1 DERIVATIVES

PUBN-DATE: September 2, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
KNUDSEN, LISELOTTE BJERRE	
HUUSFELDT, PER OLAF	
NIELSEN, PER FRANKLIN	
MADSEN, KJELD	

INT-CL (IPC): C07 K 14/605; A61 K 38/26
EUR-CL (EPC): A61K038/26; A61K038/28, C07K014/605

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

21. Document ID: WO 9943705 A1

L5: Entry 21 of 25 File: EPAB Sep 2, 1999

PUB-NO: WO009943705A1
DOCUMENT-IDENTIFIER: WO 9943705 A1
TITLE: N-TERMINALLY TRUNCATED GLP-1 DERIVATIVES

PUBN-DATE: September 2, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
KNUDSEN, LISELOTTE BJERRE	
HUUSFELDT, PER OLAF	

INT-CL (IPC): C07 K 14/605; A61 K 38/26; A61 P 3/04; A61 P 3/10; A61 P 5/50
EUR-CL (EPC): A61K038/26; A61K038/22, A61K038/28 , C07K014/605

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

22. Document ID: WO 200157084 A1 AU 200128327 A

L5: Entry 22 of 25 File: DWPI Aug 9, 2001

DERWENT-ACC-NO: 2001-514598
DERWENT-WEEK: 200173
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Producing crystals of glucagon-like peptide-1 analog for preparing pharmaceutical composition, by preparing aqueous solution comprising the analog, salt and organic solvent, and isolating crystals after formation

INVENTOR: ARENTSEN, A C

PRIORITY-DATA: 2000DK-0000156 (January 31, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200157084 A1	August 9, 2001	E	033	C07K014/605
AU 200128327 A	August 14, 2001		000	C07K014/605

INT-CL (IPC): A61 K 38/26; C07 K 14/605

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PWIC | Draw Desc | Image

23. Document ID: US 6458924 B2 US 20010011071 A1

L5: Entry 23 of 25 File: DWPI Oct 1, 2002

DERWENT-ACC-NO: 2001-595691
DERWENT-WEEK: 200268
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Composition used for treating diabetes and obesity, comprises human glucagon-like peptide-1 derivatives and surfactant

INVENTOR: BJORN, S E; HUUSFELDT, P O ; KAARSHOLM, N C ; KNUDSEN, L B ; MADSEN, K ; NIELSEN, P F ; OLSEN, H B ; PEDERSEN, F Z

PRIORITY-DATA: 1998DK-0000509 (April 8, 1998), 1996DK-0000931 (August 30, 1996), 1996DK-0001259 (November 8, 1996), 1996DK-0001470 (December 20, 1996), 1998DK-0000263 (February 27, 1998), 1998DK-0000264 (February 27, 1998), 1998DK-0000268 (February 27, 1998), 1998DK-0000272 (February 27, 1998), 1998DK-0000274 (February 27, 1998), 1998EP-0610006 (March 13, 1998), 1998DK-0000507 (April 8, 1998), 1998DK-0000508 (April 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6458924 B2	October 1, 2002		000	A61K038/16
US 20010011071 A1	August 2, 2001		133	A61K038/00

INT-CL (IPC): A61 K 38/00; A61 K 38/16; A61 K 38/26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PWIC | Draw Desc | Image

24. Document ID: WO 9964060 A1 JP 2002517468 W AU 9946697 A NO 200006194 A EP 1094834 A1 CZ 200004491 A3 AU 738994 B ZA 200004080 A US 6348447 B1 HU 200103147 A2

L5: Entry 24 of 25 File: DWPI Dec 16, 1999

DERWENT-ACC-NO: 2000-147077
DERWENT-WEEK: 200242
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Use of gastrointestinal peptide hormone for the treatment of functional dyspepsia and/or irritable bowel syndrome in humans

INVENTOR: EFENDIC, S; HELLSTROEM, P ; HELLSTROM, P

PRIORITY-DATA: 1998SE-0002080 (June 11, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9964060 A1	December 16, 1999	E	020	A61K038/26
JP 2002517468 W	June 18, 2002		020	A61K038/26
AU 9946697 A	December 30, 1999		000	A61K038/26
NO 200006194 A	January 25, 2001		000	A61K000/00
EP 1094834 A1	May 2, 2001	E	000	A61K038/26
CZ 200004491 A3	May 16, 2001		000	A61K038/26
AU 738994 B	October 4, 2001		000	A61K038/26
ZA 200004080 A	December 24, 2001		026	A61K000/00
US 6348447 B1	February 19, 2002		000	A61K038/00
HU 200103147 A2	January 28, 2002		000	A61K038/26

INT-CL (IPC): A61 K 0/00; A61 K 38/00; A61 K 38/04; A61 K 38/26; A61 K 38/31; A61 P 1/00; A61 P 1/14; A61 P 43/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

25. Document ID: WO 9943341 A1 ZA 9901570 A AU 9926107 A EP 1061946 A1 US 6268343 B1 JP 2002504518 W JP 2002506792 W

L5: Entry 25 of 25 File: DWPI Sep 2, 1999

DERWENT-ACC-NO: 1999-540500
DERWENT-WEEK: 200235

TITLE: Composition containing stabilized derivatives of glucagon-like peptide-1 with high alpha-helix content, for treating diabetes and obesity

INVENTOR: BJORN, S E; HUUSFELDT, P O ; KAARSHOLM, N C ; KNUDSEN, L B ; NIELSEN, P F ; OLSEN, H B ; MADSEN, K ; PEDERSEN, F Z

PRIORITY-DATA: 1998DK-0000272 (February 27, 1998), 1998DK-0000268 (February 27, 1998), 1999ZA-0001570 (February 26, 1999), 1996DK-0000931 (August 30, 1996), 1996DK-0001259 (November 8, 1996), 1996DK-0001470 (December 20, 1996), 1998DK-0000263 (February 27, 1998), 1998DK-0000264 (February 27, 1998), 1998DK-0000274 (February 27, 1998), 1998DK-0000508 (April 8, 1998), 1998DK-0000509 (April 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9943341 A1	September 2, 1999	E	062	A61K038/26
ZA 9901570 A	November 24, 1999		063	C07K000/00
AU 9926107 A	September 15, 1999		000	A61K038/26
EP 1061946 A1	December 27, 2000	E	000	A61K038/26
US 6268343 B1	July 31, 2001		000	A61K039/16
JP 2002504518 W	February 12, 2002		083	A61K038/26
JP 2002506792 W	March 5, 2002		087	C07K014/605

INT-CL (IPC): A61 K 38/26; A61 K 39/16; A61 K 47/00; A61 P 3/04; A61 P 3/10; A61 P 5/50; A61 P 43/00; C07 K 0/00; C07 K 14/00; C07 K 14/605; C12 N 15/09

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Term	Documents
GLUCAGON	5291
GLUCAGONS	85
LIKE	2458585
LIKES	4717
PEPTIDE-1	531
PEPTIDE-1S	0
PHARMACEUTICAL	240735
PHARMACEUTICALS	68968
COMPOSITION	1274695
COMPSN	391274
(GLUCAGON ADJ LIKE ADJ PEPTIDE-1 SAME PHARMACEUTICAL ADJ COMPOSITION).USPT,PGPB,EPAB,DWPI,TDBD.	25

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page